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Abstract 
 
Lung cancer is a leading cause of death worldwide. Genetic features like 
KRAS mutations are known to be a risk factor. The GTPase switcher RAS takes 
part on many aspects of the cell pathway and signal transduction. Example of 
that is its recognized involvement in cell survival, proliferation, metabolism, 
motility, immune response and many others. RAS constitutive activation driven 
by the common G12D KRAS mutation is responsible for numerous cancer 
hallmarks. 
To date, direct target of the mutant KRAS is still poorly efficient. Despite 
all the efforts and continuous advances in targeting either upstream and 
downstream KRAS effectors, there is still a long path to be taken with dubious 
questions to be answered. Several inhibitors are already in clinic, however the 
ability of RAS to compensate targeted pathways, and activate other effector 
kinases reduces their efficiency in the clinical setting. Other difficulty in the 
drug development field is to extrapolate the in vitro results to in vivo 
predictions. In this regard, 3D cultures are known to better model the in vivo 
situation than the frequently used 2D cultures. In vivo morphologic, 
physiologic, pathologic and functional environmental features of the tumor 
biology are aspects that can be simulated by 3D models, better predicting and 
evaluating therapeutic outcomes. 
In this work, 3D culture models of NSCLC (non-small cell lung cancer) cell 
lines have been developed along with an appropriate method to monitor cell 
viability in spheroids. The presence of an artificial extracellular matrix is shown 
to support proliferation and survival of NSCLC, promoting a non-anchorage 
independent multicellular growth. 3D models are also shown here to encourage 
cell structural organization and differentiation. Besides, the activity of p-ERK is 
especially elevated in these systems. A metabolic ATP-based viability test 
integrated with an efficient cell lysis is described as being an efficient, sensitive 
and accurate tool to evaluate the viability of spheroids. It is also shown that 2D 
and 3D culture cells have different sensitivities to drug treatments. Whereas 3D 
cultures are mostly vulnerable to structural stability disruption and PKC 
inhibition, 2D cultures show increased sensitivity upon MEK inhibition. 
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Nevertheless, vulnerabilities and KRAS dependency is cell line dependent and 
variability can be found between 2D and 3D models. However, results do not 
diminish the importance of using 3D cultures as valuable platforms to get better 
in vivo therapeutic predictions. It can eventually be the tool we are lacking to 
find new target therapies. It is therefore still a work in progress awaiting for a 
large-scale drug screen in order to highlight potential 3D exclusive drug 
candidates. 
 
Keywords: 3D cell culture; spheroid viability assay; lung cancer; NSCLC; KRAS 
pathway inhibition; drug screening. 
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Resumo 
 
O cancro do pulmão é uma das principais causas de morte no mundo. Só 
em 2012 na Europa cerca de 388.000 mortes foram registadas. Apesar da 
existência de algumas drogas eficazes para o tratamento do cancro do pulmão, 
o reaparecimento da doença é frequente após o tratamento. A aquisição de 
mutações pontuais que causam resistência e aparecimento de vias de 
sinalização alternativas e compensatórias é a principal causa. 
Apesar da conhecida associação do cancro do pulmão com o tabagismo, 
outros fatores de risco são conhecidos. Entre os principais, conta-se a história 
familiar. Alterações genéticas incluem na maioria dos casos mutações nos genes 
p53, Bcl2, Rb, FHIT e p16INK. Perda de heterozigotia, mudanças em telomerases e 
a ativação constitutiva do oncogene KRAS são também evidentes fatores de 
risco. 
Dentro do vasto painel de mutações para KRAS, pode contar-se como mais 
comum a G12D, responsável pelo desenvolvimento do subtipo cancro do 
pulmão de células não-pequenas (NSCLC), um dos mais agressivos. 
A proteína RAS é codificada pelo gene KRAS. Pertence à família das 
GTPases e tem como função molecular a ativação e desativação por fosforilação 
de GDP a GTP e vice-versa. Está envolvida numa longa cascata de transdução 
do sinal responsável pela proliferação e sobrevivência celular. As mutações em 
KRAS têm portanto um papel fundamental no aparecimento e desenvolvimento 
do cancro. A sua ativação constitutiva leva à continua estimulação das vias de 
sinalização a jusante promovendo a constante proliferação e sobrevivência, 
reprogramação metabólica, reorganização do citoesqueleto, inflamação e 
remodelação do microambiente para adaptação tumoral. 
Até à data, a direta inibição do mutante KRASG12D tem-se revelado 
impossível. Contudo, a proteína RAS encontra-se no topo de uma bifurcação de 
sinalização, tendo como principais alvos cinases como RAF, MEK, AKT e PI3K. 
Deste modo, alguns inibidores têm sido desenvolvidos nos últimos anos com o 
objetivo de bloquear alguns destes efetores tanto a montante como a jusante das 
vias de sinalização RAS. Inibidores das proteínas MEK e PI3K são dois casos já 
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clinicamente aprovados. Contudo, os progressos têm sido frequentemente 
atenuados devido à enorme capacidade da proteína RAS em alcançar inúmeras 
vias de sinalização alternativas e compensatórias, apontando para a 
necessidade do uso de terapias combinadas. 
O laboratório de Julian Downward, tem reunido esforços valiosos para a 
identificação de dependências exclusivas do mutante KRAS. A título de 
exemplo foi demonstrado que os inibidores MEK são seletivamente tóxicos para 
o mutante KRAS, enquanto o mesmo já não acontece para os inibidores de 
PI3K. Complementarmente, foram identificadas algumas dependências 
seletivas do mutante KRAS para atividades que não são diretamente reguladas 
pelo oncogene RAS. O mutante KRAS é por exemplo dependente da cinase de 
ligação 1 (TBK1), da cinase-1 ativada pelo fator de crescimento transformador β 
(TAK1), do fator de transcrição GATA2, da ciclina dependente de cinases 
CDK4, de alguns reguladores mitoticos, componentes do proteassoma entre 
outros. 
A grande maioria do conhecimento científico adquirido nesta área foi 
desenvolvido em culturas celulares em mono-camada com linhas celulares 
originárias de tumores de pacientes. Contudo, a sua manutenção prolongada 
em cultura conduz a um inevitável estado de adaptação e dependência gerados 
pela adição continua de suplementos ao meio de cultura. Este ambiente 
artificial leva à acumulação de mutações, e quando comparadas com células in 
situ, diferenças a nível molecular como diferentes expressões de marcadores de 
diferenciação, adesão e recetores de fatores de crescimento, podem ser 
encontradas. A credibilidade destes métodos em representar o tumor original e 
a confiança com que podem fornecer informações acerca de previsões clinicas 
começa então a ser posta em causa.  
O desenvolvimento de novos fármacos requer modelos que possam 
simular exatamente as condições in vivo e que possam ter relevância clínica. 
Desta forma, os modelos de cultura tridimensionais (3D) têm ganhado ênfase 
dentro da comunidade científica devido à sua capacidade em reproduzir a 
situação in vivo. Estas são conhecidas por manter o fenótipo de células tumorais 
funcional e copiar características morfológicas, fisiológicas, patológicas e 
ambientais do tumor. A organização de uma estrutura multicelular e o 
microambiente envolventes têm um impacto notório na sobrevivência e 
progressão tumoral. Estes têm também um papel fundamental na expressão 
genética, fenótipo e resposta/sensibilidade a diferentes inibidores terapêuticos. 
As culturas 3D são capazes de abranger todas estas características, eliminando 
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algumas das desvantagens presentes nas culturas bidimensionais (2D). São 
portanto uma ferramenta bastante promissora no que diz respeito ao 
desenvolvimento rápido de novas terapias, diminuindo custos de estudos 
preliminares e indo de encontro ao progresso farmacêutico e clínico. 
Neste projeto, dado as descritas vantagens dos modelos 3D, foi 
desenvolvido um método 3D que permita o crescimento e sobrevivência celular 
de NSCLC conjuntamente com um método que permita a monitorização da 
viabilidade celular em esferoides. Seguidamente, tendo em conta as 
vulnerabilidades da mutação KRAS e as suas dependências já mencionadas 
anteriormente, foram realizados testes de comparação 2D e 3D com o intuito de 
averiguar quão dependente a via de sinalização RAS é do método de cultura 
implementado. Pretendeu-se estudar que tipo de diferenças morfológicas, de 
sinalização e sensibilidade a inibidores existiam que pudessem conferir maior 
sensibilidade a culturas 2D ou 3D. 
Vários métodos de cultura celular 3D já são conhecidos.  Suspensões 
celulares podem ser usadas principalmente para formar simples aglomerados 
celulares. Superfícies antiaderentes são uma opção, assim como a técnica da 
hanging-drop, onde suspensões celulares são cultivadas em pequenas gotas 
invertidas num meio especificamente viscoso e controlado. Forças 
gravitacionais induzem a formação de esferas de colónias celulares. 
Alternativamente, culturas envoltas em componentes da matriz extracelular, 
como matrigel, metilcelulose, fibronectina, laminina e colagénio formam 
esferoides com características específicas do tumor original. Este tipo de método 
permite a interação célula-célula e célula-matriz, permitindo inclusive o 
crescimento e sobrevivência de células dependentes de ancoragem.  
Resultados demonstraram que culturas em matrizes com componentes da 
matriz extracelular, no caso testado em 2.5% (v/v) de matrigel, são 
fundamentais para a sobrevivência celular de NSCLC, determinando em certos 
casos uma definida organização estrutural e diferenciação celular. 
Métodos para o controlo da viabilidade celular também se encontram 
disponíveis no mercado, contudo a exata determinação da viabilidade em 
esferas está limitado à capacidade de penetração dos reagentes indicadores nas 
mesmas. Propriedades de lise são fundamentais para uma maior sensibilidade, 
atribuindo as maiores vantagens ao ensaio CellTiter-Glo cujo sinal de 
fluorescência é proporcional à quantidade de ATP as células. 
Resultados demonstram ainda que os níveis de actividade de p-ERK estão 
especialmente elevados quando as células são cultivadas em 3D, mas que as 
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demais proteínas envolvidas nas vias de transdução do sinal RAS como p-AKT 
e p-MLC, não se encontram particularmente alteradas entre os dois métodos de 
cultura celular. 
Diferenças entre 2D e 3D relativamente a dependências do mutante KRAS, 
foram também estudadas. Primeiramente, um teste com uma biblioteca de 384 
inibidores de cinases foi corrido automaticamente em esferas e comparado 
diretamente com um ensaio independente em 2D para uma linha celular 
diferente mas com a mesma mutação KRAS. A análise dos dados salientou 10 
inibidores como tendo um efeito citotóxico nos esferoides e um efeito oposto de 
crescimento celular nas culturas 2D. A partir deste ponto novos testes em escala 
mais pequena foram realizados e novos inibidores, conhecidos por conferir 
vulnerabilidade às células com a mutação KRAS foram usados. A respetiva 
viabilidade celular foi monitorizada em 2D e 3D para concentrações crescentes 
de inibidor.  
Dentro da lista de inibidores candidatos usados podem contar-se 
inibidores das proteínas MEK, PI3K, IKK, PKC, CDK, mTOR, TGF-β, LDH-A, c-
Met, Rho e FAK, assim como inibidores do proteassoma e destabilizadores 
estruturais como a Latrunculina e Paclitaxel. Resultados sugerem que em 
comparação com culturas 2D, as 3D são especialmente sensíveis a drogas que 
interferem com a organização da estrutura celular, como é o caso de 
estabilizadores da tubulina e inibidores da actina. Culturas 3D demonstram 
também maior sensibilidade perante inibidores da proteína cinase C (PKC) 
enquanto que culturas 2D são mais vulneráveis a inibidores MEK. Contudo, os 
resultados indicam ainda que a dependência KRAS é especifica de cada 
linhagem celular, uma vez que variabilidades entre 2D e 3D podem ser 
encontradas de caso para caso. 
Tentativas preliminares de recriar um modelo knockdown especificamente 
para o mutante KRAS, com RNA de interferência (siRNA), tiveram pouco 
sucesso. No entanto o desenho deste modelo geneticamente modificado terá 
significância para futuros testes com culturas 3D. O knockdown dum oncogene 
importante como KRAS torna as células bastante sensíveis. Um modelo estável 
funcionará como controlo em novos ensaios e determinará a especificidade e 
atribuição dos resultados à mutação KRAS. 
Os resultados alcançados não desvalorizam a importância do uso de 
plataformas 3D como forma de obter melhores previsões terapêuticas. Pode 
eventualmente ser a ferramenta indicada para encontrar novos alvos 
terapêuticos melhorando as perspetivas de tratamento. É porém um trabalho 
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ainda em progresso que espera novos testes automáticos com largas gamas de 
inibidores de forma a expor potenciais drogas com exclusiva vulnerabilidade 
KRAS em culturas 3D. 
 
Palavras-chave: cultura celular 3D; Teste de viabilidade em esferoides; Cancro 
do pulmão; NSCLC; Inibição da via KRAS; drug screening. 
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Terminology and Abbreviations 
 
2D - two dimensional 
3D - three dimensional 
AKT - Protein kinase B 
CDK - Cyclin-dependent kinase 
CSCs - Cancer stem cells 
CTB - CellTiter-Blue 
CTG - CellTiter-Glo 
DAPI - 4',6-diamidino- 2phenylindole 
DMEM - Dulbecco's modified eagle medium 
DMSO - Dimethyl sulfoxide 
EDTA - Ethylenediamine tetraacetic acid 
EGFR - epidermal growth factor receptor 
EHS - Engelbreth-Holm-Swarm 
EM - Electron microscopy 
ERK - extracellular signal regulated kinase 
FACS - Fluorescence activated cell sorting 
FAK -  Focal adhesion kinase 
FBS - Fetal bovine serum 
FITC - Fluorescein isothiocyanate 
GAPs - GTPase activating proteins 
GATA2 - Gene encoding for GATA binding 
protein 2 
GEFs - Guanine nucleotide exchange factors 
GFP -  Green fluorescent protein 
H&E - Hematoxylin and eosin 
HRAS - Harvey rat sarcoma viral oncogene 
homolog 
ICx - x% of inhibitory concentration 
IKK -  IκB kinase 
KRAS - Kirsten rat sarcoma viral oncogene 
homolog 
LDH-A - Lactate dehydrogenase A 
MAPK - Mitogen-activated protein kinase 
MEK - Mitogen-activated protein kinase 
kinase 
mTOR - Mammalian target of rapamicyn 
NRAS - Neuroblastoma RAS viral (v-ras) 
oncogene homolog 
PBS - Phosphate-buffered saline  
PI3K - Phosphatidylinositide 3-kinase 
PKC - Protein kinase C 
PMSF - phenylmethylsulfonyl fluoride 
PVDF - Polyvinylidene difluoride 
qPCR - quantitative polimerase chain reaction 
RAF - effector of RAS 
RAS - Family of GTPases 
RB - Retinoblastoma protein 
Rho - GTPase 
SDS-PAGE - Sodium dodecyl sulfate 
polyacrylamide gel electrophoresis 
SNAIL2 - Tanscriptional repressor 
TBST - Tris-Buffered Saline and Tween 20 
TCA - Tricarboxylic acid cycle 
TEM - Transmission electron microscopy 
TGF-β - Transforming growth factor beta 
TICs - Tumor initiating cells 
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Chapter 1 
 
 
Introduction 
 
1.1- Lung cancer 
 
Lung cancer is a leading cause of death being the most frequent malignant 
disease worldwide [1]. 
Only in the Europe, in 2012, around 388.000 people died from this disease 
[2]. The restricted early detection along with the low therapeutic improvements 
is considered the major cause for the low survival rate, around 15% [3]. Despite 
the existence of several efficient drugs approved for the lung cancer treatment, 
the recurrence after treatment is very frequent, due to the acquisition of 
resistant point mutations and alternative compensatory pathways beyond the 
targets of therapy [4], [5].  
Thus, the need for the discovery of new targets, allowing the development 
of new therapies is urgent. Advances in this area will hopefully bring further 
insights to help clinicians curing patients battling with this disease, providing 
them a longer lifespan and quality of life. 
 
However, in these days, lung cancer is still a disease with a poor prognosis 
for patients. Among lung cancer, we can distinguish three types 
morphologically different: The carcinoids that are neoplasms of neuroendocrine 
origin [6]; The small cell lung cancer (SCLC), which is less prevalent, is 
characterized by the microscopic presence of round small cells with limited 
cytoplasm mostly filled with the nucleus [7]; And the non-small cell lung cancer 
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(NSCLC), which is the most common type affecting more than 80% of the 
diagnosed patients with lung cancer. This type is generally subdivided into 
three main groups comprehending squamous cell carcinoma, adenocarcinoma 
and large cell carcinoma [8], [9]. The first, being the most frequent, develops 
from the squamous cells that line the airways and it is often found near the 
centre of the lung in the bronchus. Adenocarcinoma grows slowly and is arising 
from the cells that usually secrete substances like mucus and it is found in the 
outer areas of the lungs. Large cell carcinoma can appear in any part of the lung 
and tends to grow and spread quickly [10]. 
Apart from the well known association of lung cancer with smoking, other 
risk factors arise from a positive family history of the disease. Genetic 
alterations include, in most of the cases, mutations in the p53, Bcl2, Rb, FHIT or 
p16INK genes. Moreover, telomerase changes, lost of heterozygosity and 
mutations that activate the KRAS oncogene have also been described as risk 
factors [1], [10]. 
 
 1.1.1- RAS oncogene and signalling pathway 
 
The most prevalent drivers of human cancer are the 3 isoforms of RAS 
proteins, encoded by KRAS, NRAS and HRAS genes. KRAS activating 
mutations were described as being the most frequent in cancers [11]. The 
distribution of mutations for this particular oncogene points out the importance 
of G12D, the most recurrent mutation [12]. 
RAS proteins are GTPases that function as molecular switchers of GDP into 
GTP, playing a key role in the signal transduction involved in the cell survival 
and proliferation. RAS activation is catalyzed by guanine nucleotide exchange 
factors (GEFs) to a GTP-RAS state and it is inactivated by GTPase activating 
proteins (GAPs) to its GDP-RAS state by hydrolysis (Figure 1) [11], [13]–[15].  
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Figure 1. Ras upstream signalling. RAS is activated by GEFs and inactivated by GAPs. When 
RAS is mutated these interactions are broken compromising the normal cell signalling. (Julian 
Downward 2002) 
 
KRAS mutations are known to impair GTPase activity blocking the 
interaction between KRAS and GAPs leading to its constitutive activation [16]. 
KRAS proteins are thus important players in the cancer development. Its 
mutation leads to the persistent downstream signalling pathway stimulation, 
promoting therefore many cancer hallmarks such as uncontrolled cell 
proliferation, enhanced survival, metabolic reprogramming, cytoskeletal 
reorganization, increased motility, inflammation and microenvironment 
remodelling for tumor adaptation [14], [16].  
RAS has been described to stand at the top of a bifurcation for a vast 
network of signalling pathways, targeting several kinases, being the most 
important ones: RAF, MEK, ERK, AKT and PI3K proteins (Figure 2) [15].  
 
 
 
 
 
 
 
 
Figure 2. Ras downstream signalling. RAS is involved in the activation of several pathways, 
controlling several aspects of the cell proliferation, survival and transcription. (Julian 
Downward 2002) [15]. 
 
Although it has been demonstrated that tumor cells with KRAS mutations 
are dependent on KRAS activity, targeting directly RAS has been demonstrated 
to be clinically a challenge to date. It is very difficult to design inhibitors for 
GTPases. Targeting downstream proteins has therefore becoming a focus of 
attention in the majority of recent studies. Exploiting new possibilities of 
efficient targets has been constant. Despite the existence of clinically approved 
inhibitors for downstream effectors of RAS, the ability of RAS to achieve 
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multiple pathways at different stages has also unveiled the importance of using 
combined therapies [12], [16], [17].  
MAPK pathway, commonly activated in many cancers, leads to RAS 
activation via adaptor proteins that consequently activate the RAF/MEK/ERK 
kinase cascade. AKT/PI3K pathway is a parallel pathway that regulates the 
same functional transcription factors as ERK pathway. Indeed, there are 
multiple points of crosstalk between these two pathways. They have been 
described to influence each other at different stages of the signal propagation, 
determining together the cell fate in a complex and dynamic range of positive 
and negative loops. This crossed network is a very robust system that shows 
poor vulnerability to external perturbations [18]–[20].  
However, several inhibitory molecules against either MEK or PI3K have 
been developed with favorable clinic significance and are now under clinical 
trial. Combination of inhibitory drugs for both targets are also in early-phase 
clinical trials, with still unclear efficacy and toxicity [21]. Importantly, MEK 
inhibitors were shown to be selectively toxic for the KRAS mutant genotype 
whereas PI3K inhibitors did not. Moreover tumors with KRAS mutations were 
also shown to be selectively dependent on activities that are not directly 
regulated by RAS. The identification of those factors and pathways that are 
particularly essential only for cells bearing an activated RAS oncogene, have 
already been approached with lethal RNA interference screens. The binding 
kinase 1 (TBK1), the transforming growth factor β–activated kinase 1 (TAK1), 
the transcription factor GATA2, the CDK4, mitotic regulators and proteasome 
components appeared as prominent good candidates [21], [22]. Particular 
dependencies can also be attributed to SNAIL2 in case of the cells that have 
undergone epithelial mesenchymal transition [23], [24], and MEK, that brings 
dependencies on RAS mutant cells, along with the insulin-like growth factor 
receptor (IGF1-R) tyrosine kinase input signal [21].  
 
1.2- 3D cultures 
 
Most of the knowledge brought into light over the past few years has been 
achieved by pre-clinical cancer therapy research in several cancer cell lines. 
These cell lines often arise from patient tumors and undergo long term 
cultivation under specific circumstances. This drags them into a serum-supplied 
adaptive state, environmentally artificial, known to enhance the accumulation 
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of genetic alterations. Comparing to in situ cells, differences at the molecular 
level have also been identified, including different expressions in differentiation 
markers, adhesion and growth factor receptors. Questions come up about the 
reliability of these models regarding its accuracy in representing the tumors of 
origin and about its ability to be loyally correlated with clinical predictions [4], 
[25]. 
Furthermore, cancer drug development and testing requires relevant cell-
based models that can simulate very closely the in vivo situation when comes to 
the point of detecting rapidly the best active drug candidates from large pools 
of prospective effectors. In this sense, three-dimensional (3D) culture models 
have been gaining recognition among the scientific community due to its ability 
to better mimic the in vivo conditions, keeping the functional phenotype of 
tumor cells, and better evaluate therapeutic clinical interventions [26], [27]. 
3D platforms are valuable tools able to restore morphologic, physiologic, 
pathologic and functional environmental features of the tumor biology. They 
bring further insight about tumor organization, homeostasis and cellular 
differentiation. Moreover, the microenvironment and the surrounding 
extracellular matrix have been described to play a notorious role into the tumor 
survival and progression. It also has an impact in the phenotype, gene 
expression and responsiveness/sensitiveness towards different therapeutic 
drugs [28]–[30]. Along with these characteristics, 3D cultures are also known to 
present stronger cell-cell interactions and have a nutrients and oxygen delivery 
gradient system more similar to in vivo. This has thus been contributing to the 
understanding of altered responses comparing to 2D cultures [26], [27].  
In this sense, 3D cultures are promising tools that can improve clinical 
efficacy predictions, bringing faster results and new anticancer therapeutic 
strategies. It may also reduce experimental costs, avoid unnecessary 
preliminary trials and replace some animal tests, which is undoubtedly a step 
forward for the researchers and pharmaceutical industry [31], [32].  
 
 1.2.1- 3D culture systems 
 
Currently there are several 3D in vitro culture methods. Not all of them 
work for all the cell lines and some require very specific instruments, being 
hardly reproducible. Among others, 3D cultures include shaking-based 
approaches, non-adherent round surfaces, microfluidic systems, hanging-drop 
techniques, scaffold-based models, cell printing and matrix embedding. The 
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latter uses extracellular matrix proteins like matrigel, methylcellulose, 
fibronectin, laminin and collagen. 
Suspension methods as non-adherent surfaces on repulsing substrates and 
hanging-drop techniques generate simple aggregates of cells. Hanging-drops 
are drops of cells in suspension which are then inverted. The specific viscosity 
of the media within which they are seeded determines the right properties for 
its hanged sustention. In this case, gravitational-enforced cell settling and cell-
cell adhesion leads to the self-assemble of spherical clusters of cell colonies 
(Figure 3) [32].  
Alternatively, matrix embedding techniques allow the formation of 
spheroids with tumor specific features. This sort of methods overcome the lack 
of cell-surface adhesion of the traditional 3D cultures, which are very often 
known to impair cell survival of anchorage dependent cells.  Matrix embedded 
cells have both cell-cell and cell-matrix attachments. When proteins from the 
extracellular matrix are incorporated in the culture medium, tissues structure 
and some of their differentiated functions are preserved (Figure 3). Matrigel is 
one of the most commonly used materials to construct 3D models. It is a 
basement membrane preparation extracted from the EHS mouse sarcoma that is 
rich in extracellular matrix proteins, including laminin, collagen IV and 
entactin. Altogether they form an organized structure able to sustain cell 
growth and survival [32], [33].  
  
 
 
 
 
Figure 3. 3D culture systems. Matrice embedding maintains structural and functional 
properties of tumor cells. Cell suspension and hanging-drops form spontaneous agglomerates 
of cells. 
 
 Additionally, once the sustained proliferation is a characteristic of tumor 
cells, all 3D models must allow the monitoring of cell viability. Plus, most of the 
results from drug assays are mainly based on the survival of cells, reinforcing 
the importance of gather 3D models with an accurate viability test.  
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 There exist viability tests based on the metabolic activity of cells, the 
presence of ATP or other redox metabolites. Cells' ability to metabolize and 
react with certain products are afterwards detected mostly by spectroscopy and 
correctly quantified, being the results correlated with the amount of live cells. 
Other methods are based on investigating cells' integrity or the presence of 
certain molecules or markers well known to trigger apoptosis [34].  
 
1.3- 2D vs 3D differences 
  
 Bearing in mind the advantages of 3D culture models, efforts to recreate 
this kind of platforms with NSCLC cells appear to be a new priority. Such 
efforts will definitely bring more reliable results either on drug screens or in the 
understanding of simple signalling pathways. 
 In this sense, comparing 2D and 3D cultures is essential to understand 
whether it can convey major differences that may underestimate 2D culture 
experiments.  
 Specifically, understanding how dependent RAS pathway is from the 
culture method and how different the already observed characteristics of 
mutant KRAS cell lines are from the culture system, can surely bring new 
insights and perhaps, change the way assays should be done in order to get 
closer approaches to the in vivo situation.   
 Comparisons involve then morphologic features, signalling pathway 
aspects and examination of the different sensitivities and vulnerabilities 
towards drug treatments. 
 
 1.3.1- Targeting KRAS effectors 
 
As has already been described before, Julian Downward’s lab has 
investigated unique dependencies of RAS mutant cancer cells over the past 
years, highlighting a number of vulnerabilities of RAS mutant cells [21], [22]. 
One term of comparison between 2D and 3D cultures was therefore the use of a 
selection of effectors that have already been demonstrated to be essential for the 
survival of KRAS mutant cells.  
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The urgent need to test several of these established effective inhibitors on 
3D cultures in an attempt to find divergences that would eventually refute 
previous results made in 2D cultures was subject of study for NSCLC cell lines. 
 
  1.3.1.1- Candidate inhibitors 
 
In order to compare KRAS dependencies in 2D and 3D settings, several 
inhibitors were tested. That includes drugs targeting KRAS downstream 
effectors or other pathways that have been demonstrated to be important for 
the survival of cells harboring KRAS mutations [15]. 
 
- MEK inhibitors - Permanent active forms of MEK are implicated in the 
development of several human cancers [35]. Targeting the mitogen activated 
protein kinase (MAPK) pathway with highly selective inhibitors of MEK has 
been proved to inhibit efficiently ERK activation. Therefore blocking 
proliferation, survival and motility of in vitro tumor cell lines under certain 
circumstances. It has also been proved to be effective on the growth inhibition 
of tumors in immunodeficient mice [15], [36].  
 
- PI3K inhibitors - KRAS mutations also lead to growth stimulation 
through AKT activation, because of the crosstalk between ERK and PI3K/AKT 
activation. Consequently, regulation of each other determines the efficacy of 
MEK inhibitors [3], [18]. Breaking down this ERK/PI3K interaction seems then 
to be a good target, as was already observed in vivo assays [16], [37].  
 
- Proteasome inhibitors - Along with the previous kinase inhibitors (MEK 
and PI3K inhibitors), there is also a clear need to interfere with the largely 
studied kinase/protease crosstalk, which can be achieved by proteasome 
inhibition. Many kinases are regulated by proteolytic cleavage and in turn, 
many other proteases activity can be switched on or off by phosphorylation 
[38].  
 
- IKK inhibitors - NF-kB proteins are transcription factors that have been 
described as having an important role in inflammatory diseases. Abnormal 
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regulation of these proteins can lead to autoimmune diseases and several types 
of cancer. Regulation of NF-kB is carried out in part by IKK. Moreover, IKK-β 
activity is required for protection from apoptosis. Efforts to inhibit IKK have 
then been matter of interest. IKK inhibition has also been proven to be effective 
in reducing lung cancer cell proliferation in vitro and blocking tumor growth in 
vivo especially for patients with KRAS mutation [17], [39]. 
 
- PKC inhibitors - Protein kinase C family regulates a diverse set of cell 
processes such as cell survival, proliferation, migration and apoptosis, being 
ultimately involved in malignant transformation when cooperating with RAS. 
Different isozymes are responsible for the activation of AKT and ERK, 
increasing anchorage-independent growth, metastasis and tumorigenicity. Its 
inhibition was then a target for the NSCLC cells 3D models [40], [41].  
 
- CDK inhibitors - Cyclin-dependent kinases are important cell-cycle 
regulators. CDK4/CDK6 are activated by cyclin D1, which in turn is regulated 
by many signalling intermediates including RAS-MEK-ERK and PI3K-AKT 
pathways. Increased activation of cyclin D1-CDK4/CDK6 leads to the 
phosphorylation of RB (retinoblastoma protein), which induces the 
transcription of E2F-responsive genes increasing proliferation. Therefore, 
abrogation of CDKs activity is thought to be an effective therapeutic approach 
[42].  
 
- mTOR inhibitors - mTOR is activated by PI3K, an effector of RAS 
pathway, which in turn is able to activate AKT and consequently the 
downstream pathway contributing to proliferation and cell survival. Its 
inhibition in vitro and in vivo pre-clinical models has been shown to inhibit 
proliferation [43]. 
 
- TGF-β inhibitors - In cancer cells, the MAPK upstream TGF-β regulator 
has been seen to be activated simultaneously with RAS-MAPK, acting 
synergistically in tumorigenesis [44], [45].   
 
- LDH-A inhibitors - Chemical compounds such as lactate dehydrogenase 
A (LDH-A) inhibitors, were seen to decrease tumorigenesis in NSCLC driven 
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by KRAS or EGFR oncogenes. Researchers have also seen that abrogation of 
LDH-A in tumors that rely on hypoxic niches reduces the Warburg effect in 
NSCLC in vivo and ex vivo. However reactivation of the TCA cycle happens in 
vitro reinforcing the microenvironment importance in the tumor metabolic 
reprogramming and consequent cells survival [5].  
 
- c-Met inhibitors - Literature has recently shown a Met indispensable 
dependency for anchorage-independent cell growth on KRAS mutants [46]. 
 
- Rho inhibitors - Rho GTPases are a family of RAS oncogenes that 
promote signal transduction upon binding to GTP, controlling cell morphology 
and actin cytoskeleton. Its inhibition would then attenuate the constitutive 
effectors from generating a cellular response. However the spatiotemporal 
control of Rho-GTPases might restrict its activity [47]–[49]. 
 
- FAK inhibitors - The nonreceptor Focal Adhesion Kinase (FAK) can bind 
an activate signalling proteins such as PI3-K, many times activated in KRAS 
mutant cancer. Its inhibition has also been identified as a promising anti-
tumorigenic agent [20], [50].  
 
- Latrunculin and Paclitaxel - Other approaches may also be effective when 
interfering with the structural organization of the spheres, or hamper its 
morphologic stability. In theory this strategy might bring little or no major 
harm to monolayer cells, that do not present a well defined structural 
multicellular organization, while in 3D cultures it should already been taken in 
consideration. In this same way, cytoskeleton interfering drugs such as 
Paclitaxel and Latrunculin appear to be worth trying and analyzed between 
both, 2D and 3D culture systems.  
 
1.3.2- KRAS knockdown 
 
Despite the efforts, the direct inhibition of KRAS is still not possible. 
However advances in selectively knocking down the oncogenic KRAS is known 
to be therapeutically effective and to suppress tumor growth in NSCLC. 
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Although, in certain cases targeting KRAS by itself might not be sufficient but 
leastwise it sensitizes tumor cells, opening possibilities of combining this 
strategy with other target therapies [14], [51].  
The use of small interfering RNA (siRNA) in spheroid cultures, in order to 
genetically manipulate the expression of an important oncogene like KRAS is 
valuable. Cells are very sensitive to its knockdown and effects on cell viability 
are already known. A stable model can work as a control for drug assays, 
showing specific and unique KRAS dependencies and vulnerabilities.  
 
1.4- Aim of the work 
 
3D culture models are known to better predict therapeutic outcomes due 
to its ability to better simulate the in vivo morphologic, physiologic, pathologic 
and functional environmental features of the tumor biology. Targeted 
anticancer therapies with 3D tools are still barely explored and further insights 
into this field would definitely benefit in vivo treatments. Based on that, the aim 
of this study is: 
- To set up a method that allow the survival and growth of RAS mutant 
lung cancer cells in 3D cultures; 
- To identify an accurate method to monitor cell viability in 3D cultures, 
suitable for large-scale screening; 
- To compare the dependencies of RAS mutant cells and drug 
vulnerabilities in 2D and 3D cultures. 
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Chapter 2 
 
 
Materials and Methods 
 
The aim of this work was to develop a three-dimensional culture method 
that would allow the survival and growth of KRAS mutant cell lines. The 
purpose of this methodology is to guarantee a closer approach to the in vivo 
situation of non-small cell lung cancer, providing a more effective tool to test 
clinical antitumor drugs. 
 
2.1- 3D culture methods 
 
NSCLC cell lines were previously generated in the lab and were obtained 
from KRAS mutant alone and KRAS mutant plus p53 deleted mice lung tumors 
and metastasis. All cell lines were initially grown in monolayer at 37ºC in 5% 
CO2 with normal media: Dulbecco's Modified Eagle's Medium (DMEM) with 
10% (v/v) fetal bovine serum (FBS), 1% (v/v) glutamine and 1% (v/v) 
penicillin-streptomycin antibiotic.  
 
 2.1.1- Soft agar 
 
6 well plates were initially coated with equal volumes of 1.2% (w/v) 
agarose at 42ºC in distilled water and 2x normal media to give 0.6% (w/v) 
agarose in 1x media. 
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Cells were previously washed in Phosphate-buffered saline (PBS) and 
trypsinized with 1x trypsin solution. After its collection with normal media and 
centrifugation at 1200rpm for 4min, the pellet was re-suspended in normal 
media and filtered through a standard FACS filter (70µm pore size) to 
guarantee that cells would be plate as single cells.  
 Cells were counted and 40000 cells were then plated in triplicate with 0.3% 
(w/v) agarose in 1x media at 42ºC over the previous base layer. 
After set down, normal media was dropped onto surface and repeated 
every 3 days during 3weeks. Cells were kept on 37ºC in 5% CO2. 
 
 2.1.1.1- Giemsa staining 
 
After 3 weeks on culture, colonies from soft agar cultures have been stained 
with Giemsa, a modified solution Fluka 48900: 1 part Giemsa + 5 parts 
glycerol:methanol (5:24 parts). 
Media was removed from agarose surface and 1mL of Giemsa was added 
and kept 20min under gentle agitation. Afterwards, several washes were 
carried out with water under gentle agitation, including one wash overnight.  
 
 2.1.2- Non-adherent round bottom plates 
 
Trypsinized cells were centrifuged, re-suspended and filtered to avoid 
agglomerates.  
Triplicates of 5000 cells were then platted, in Corning® 96 Well Clear 
Round Bottom Ultra Low Attachment Microplates, either with normal media or 
with media without FBS, followed by incubation at 37ºC in 5% CO2. Cells were 
kept in culture for 7 days with regular feeding. 
 
2.1.3- Non-adherent coated plates 
 
Flat bottom Corning® 96 Well plates were coated before the seeding of 5000 
cells per well.  
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 2.1.3.1- Agar coating 
 
Plates were coated with the same base layer used on soft agar protocol. 50µl 
of 0.6% (w/v) agarose (at 42ºC) in 1x normal media was added to each well and 
set down. 
 
 2.1.3.2- Polyhema coating 
 
Poly(2-hydroxyethyl methacrylate) was dissolved with ethanol in a hot 
water bath with stirring to a final concentration of 0.12g/ml (10x). The solution 
was filtered to remove impurities in a sterile syringe filter with 0,2µm pore size. 
100µl of a 10 times diluted solution was added to each well and evaporation 
happened upon incubation of the plate at 65ºC. The process was repeated once 
more before loading cells.   
 
2.1.4- Hanging drops 
  
 There are available on the market a set of plates that allow to perform 
this technique easily, however it was made inverting normal 10cm dishes.  
 A 1.25% (w/v) methylcellulose stock solution was pre-made in normal 
media, corresponding to 5x of the desired final concentration, which is 0.25% 
(w/v) methylcellulose. The solution was then diluted to 2x with normal media 
and filtered with a 0,44µm pore size syringe filter to remove impurities.  
 Cells were trypsinized and after centrifugation at 1200rpm for 4min, the 
pellet was re-suspended and filtered through a standard FACS tube to avoid 
agglomerates. Cells were then counted and a stock cells solution made with the 
amount of desire loaded cells per 10µl of normal media. Equal volume of 2x 
methylcellulose was afterwards pipetted to the stock cells solution and drops of 
20µl plated in triplicate into the lid of a 10cm petri dish (Figure 4).  
Ex.: For 10 drops with 5000 cells each, around 110µl with 55000 cells will make 
the stock cells solution. Then 110µl of 2x methylcellulose is added giving a final 
solution of 220µl of 0.25% (w/v) methylcellulose with 55000 cells. In this way, 
each 20µl drop will have 5000 cells.    
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 Distilled water was added to the bottom of the petri dish to form a wet 
chamber and the lid inverted towards the top of the dish. Drops were then kept 
at 37ºC in 5% CO2 overnight. 
 On the following day, spheres should have been formed and can easily 
be seen by eye. Each sphere was then carefully pipetted into individual 96 flat 
well plates, pre-coated with 0.6% (w/v) agar, and finally filled with 100µl of 
normal media before returning to the incubator at 37ºC in 5% CO2.  
 At this stage, cells can be kept in culture for more than one week and 
regular feeding with 25µl of normal media was ensured every 3 days.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Hanging drop technique illustration. 20µl of cells in 0.25% (w/v) methylcellulose 
are hanged on a lid that is inverted into a wet chamber. Overnight incubation under 
gravitational forces allows the cohesion of cells into spheres that can be transposed on top of 
agar coated surfaces, where they can remain alive for more than one week. 
 
2.1.5- Matrice embedding 
 
 2.1.5.1- Matrigel 
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For this procedure Matrigel® matrix basement membrane with growth 
factor reduced was supplied by Corning®. It was perform on ice and all used 
materials were properly pre-cooled at 4ºC to avoid matrigel solidification.  
Cells in 2D cultures (10cm plates) were washed in PBS and trypsinized.  
Cells were collected with normal media (10% (v/v) FBS) to a falcon tube 
and centrifuged for 4min at 1200rpm. 
The supernatant was discarded and the pellet was re-suspend in normal 
media. It was filtered through a standard FACS tube (70µm pore size) to 
remove potential clumps. 
Cells were then counted and diluted to have 2x the amount of cells to be 
plated (solution A). Ex.: For 96 wells with 2500 cells per sphere/well, solution A 
have around 265.000 cells in 5.3ml.  
On ice a 2x matrigel solution was made in normal media (solution B). 
Matrigel was gradually dissolved, pipetting up and down, with little cold 
amounts of normal media in order to achieve an homogenous solution. 
On ice, solutions A and B were mixed together in a 1:1 proportion. 
On ice, the cell-matrigel mixture was poured into disposable reservoir 
liners and with a multichannel pipet, 100μL of the content was pipetted into the 
wells. 
Afterwards, the plate was centrifuged at 1000 rpm at 4°C during 15-20secs. 
Plates were then kept at 37°C in 5% CO2. 
48h later a compact sphere should have been formed. Spheres can be kept 
in culture for more than one week with every three days feedings with 25µl of 
normal media. 
 
2.1.5.2- Methylcellulose 
 
This procedure follows the main guides from the matrigel embedding 
spheres protocol described above, but it is carried out at room temperature. 
A 1.25% (w/v) methylcellulose stock solution (5x) was pre-made in normal 
media. Before being used it is diluted with normal media into 2x and properly 
filtered with a 0,44µm pore size syringe filter to remove impurities.  
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2.2- Viability methods 
 
2.2.1- CellTiter-Blue assay 
 
This is a light sensitive end-point assay. Direct light sources were avoided 
during all the procedure. 
5µl of CellTiter-Blue was added to each well of 3D or 2D cultures including 
the respective blanks and incubated at 37ºC for 2h. In this period viable cells 
were able to convert by reduction resazurin to the fluorescent resorufin product 
(Figure 5). Plates were then read in the PHERASTAR Plus microplate reader, set 
up to read the fluorescence emition signal at 590nm.  
 
 
 
 
 
 
 
 
Figure 5. Redution of resazurin in resorufin. Fluorescence signal should be proportional to the 
number of metabolically active cells. 
 
2.2.2- CellTiter-Blue with EDTA treatment 
 
In this end-point viability assay for 3D cultures, 10µl from a 50mM EDTA 
solution was added to each well, having as final EDTA concentration 5mM. 
Plates were briefly stirred and incubated at 37ºC for 45min to allow spheres 
disruption. Therefore, 5µl of CTB was added to the wells followed by 2h 
incubation and 590nm fluorescence reading with the PHERASTAR Plus 
microplate reader. 
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2.2.3- Tryphan blue staining 
 
The use of this method is wide spread in 2D cultures for routine cell culture 
counting. To be used in 3D cultures, spheres were first disrupted with 5mM 
EDTA (final concentration) at 37ºC for 45min. Next, 10µl of the sample was 
mixed with 10µl of tryphan blue and pipetted into a cell counting slide. It was 
then inserted in a cell counting instrument and the concentration of live cells 
was automatically displayed. 
 
2.2.4- Integrated density of the GFP fluorescence 
 
The determination of the intensity fluorescent signal of spheres from 
microscopic images was done with ImageJ software.  
First, images were treated with the same software to delineate the spheres 
perimeter. To do so, threshold was established and particles above the defined 
size identified and individually selected. In this way the same mask could be 
used for the original FITC image (corresponding to the sphere GFP signal). 
Afterwards measurements were done taking in account the blank that 
correspond to the black coloured area of the image (Figure 6). 
Hereby, one of the set measurements given was the integrated density, 
with which further analysis were made.  
 
 
 
 
 
 
 
 
Figure 6. Measuring spheres fluorescence using ImageJ. Several steps were executed in order 
to get the integrated density signal of each sphere.  
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2.2.5- Acumen - GFP fluorescence signal 
 
The area of GFP positive cells could be automatically determined with 
the Acumen Explorer eX3 laser scanning microplate cytometer (TTPLabtech), 
allowing the size monitorization of spheres through time. 
 
2.2.6- CellTiter-Glo assay 
 
CellTiter-Glo® Luminescent Cell Viability assay was a product supplied 
by Promega. 
 This is a temperature dependent and light sensitive assay. In this way, 
spheres were left at room temperature for 30min along with the CellTiter-Glo 
reagent to stabilize.  
After that, 50µl of reagent was added to each well, followed by 2min of 
vigorous shaker agitation and 15min stabilization. Plates were kept away from 
direct light sources every time possible.  
Cells are then lysed and ATP is released, allowing a luciferase catalyzed 
reaction to take place. In the presence of ATP, Mg2+ and O2, luciferin is 
converted into the oxyluciferin fluorescent product by mono-oxygenation 
(Figure 7). 
Plates were then read in the PHERASTAR Plus microplate reader, with 
the correct settings for luminescence. 
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Figure 7. Conversion of luciferin into oxyluciferin. This mono-oxygenation reaction is just 
carried out in the presence of ATP that is released by lysed live cells. The signal is thereby 
proportional to the number of live cells. 
 
2.3- Morphology of spheres 
 
2.3.1- TEM and EM 
 
Images of the spheres by Transmission electron microscopy (TEM) and 
Electron microscopy (EM) was a part of the project performed by the Electron 
Microscopy facility of the Francis Crick Institute. They provided the equipment 
and expertise necessary to get high resolution images.  
Spheres were cultured under the desired conditions, 2.5% (v/v) matrigel, 
and plates were taken to the Electron Microscopy facility which took care of the 
following steps until image acquisition.   
 
2.3.2- H&E and E-cadherin staining 
 
These assays were carried out by the Experimental Histopathology facility 
of the Francis Crick Institute.  
Spheres were cultured for one week in 2.5% (v/v) matrigel. The following 
procedures for Hematoxylin and eosin stain (H&E) and E-cadherin staining 
were elaborated by the facility which provided the final images. 
 
2.4- Western blotting  
 
2.4.1- Protein extraction 
 
 Cell lysis buffer supplied by Cell Signaling was used for protein 
extraction. This 1% triton lysis buffer was prepared being previously diluted to 
1x with distilled water. 25mM of NaF and 1mM of PMSF (dissolved in ethanol) 
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as final concentrations were also added, along with 10% (v/v) of protease 
inhibitors and 1% (v/v) of the phosphatase inhibitor cocktail. 
 For protein extraction on 2D cells, 24 wells from the 96 well plates were 
used for the same conditions. 2D cells were washed twice with cold PBS, 
scraped and solubilized in cell lysis buffer. The samples were kept on ice during 
20min for better lysis. Eppendorfs were then centrifuged at 4ºC for 10min at 
13000rpm and the pellet discarded. Samples were kept at -20ºC until blotting. 
 3D protein extraction required 48 spheres with 10000 cells each for each 
condition. 3D cells were carefully taken from the plate and transferred to an 
eppendorf where they were washed three times with cold PBS to dilute the 
matrigel and remove FBS. Cells were then solubilized with cell lysis buffer and 
kept on ice for 1h pipetting up and down every 15min to disrupt spheres. They 
were then centrifuged at 4ºC for 10min at 13000rpm and the pellet discarded. 
Samples were kept at -20ºC until blotting. 
 
2.4.2- Blotting 
 
 Protein concentration of the aliquots with cell lysates was quantified with 
the bradford assay. Samples were then prepared to load into gels with 1x 
Laemly buffer plus 10% (v/v) β-mercaptoethanol. The low amount of extracted 
protein from the spheres just allowed to load 2µg of protein. 
 Aliquots were sonicated for 10sec, boiled 5min and subject of SDS-PAGE. 
Proteins were then transferred to PVDF membranes and immunoblotted with 
different antibodies.  
 For chemioluminescent detection, 5% (v/v) BSA in TBST-0.05% (v/v) 
(Tris-Buffered Saline and Tween 20) was used to block the membranes against 
nonspecific epitopes. Whereas for the LI-COR system, which is an infrared 
fluorescent detection method, the especific Odyssey® Blocking Buffer was used. 
 Primary antibodies were prepared in the corresponding blocking 
solutions in a concentration of 1:2000, apart from the p-Akt(T308) and p-
Akt(S473) which concentration was 1:750. Secondary antibodies were prepared 
as 1:5000 in blocking buffer. Vinculin is a housekeeping protein used as loading 
control. All washes were made with TBST-0.05% (v/v). 
 Re-probing membranes entailed the use of stripping buffer. 
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 Variations in protein expression levels were quantified with ImageJ 
software using densiometry values. 
 
2.5- Preliminary drug screen 
 
 Drug screen was performed by the High Throughput Screening facility 
of the Francis Crick Institute that was provided with the desired 3D cells, in this 
case MetA cell line. 
 Cells were monitored with the acumen, as already described above, and 
spheres' area measured before treatments and at 24h, 48h, 72h and 6 days after 
treatment with a kinase library drug screen for 384 wells. Single spheres 
treatment was applied and no replicates were used. Every drug was used with 
a standard concentration of 10µM. 
 
2.5.1- Determination of hit drugs 
 
 Comparisons were made between 3D cultures of MetA line and 2D 
cultures from other cell line of a previous kinase library drug screen.  
 First the fold change size of DMSO control spheres were measured 
comparing the day 6 of treatment with pre-treated spheres. A median of 424% 
fold change was found with a standard deviation of 107%. These values were 
taken into account to classify the drug effect on treated spheres. In this sense, 6 
days after treatment, drugs that produced a spheres' fold change of 317-531% 
were classified as cytostatic drugs, with null effect. Drugs that lead to fold 
changes between -100% (minimum value) and 107% were considered cytotoxic. 
Finally, fold changes above 531% categorized the drug as having a positive 
growth effect. 
 A drug cytotoxic effect was then search for 3D cultures. Taking in 
account the found drugs, a simultaneous cytostatic or growth effect was tracked 
for the available screen on 2D cultures. In this case, cells' confluence was 
measured and drugs with values above 10 were assumed to have enhanced cell 
growth. 
 Thereby, 10 different inhibitors were selected and subject of further 
analysis. 
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2.6- Drug assays 
 
For all drug assays, 2500 cells in 2.5% (v/v) matrigel were used for 3D 
cultures and 1000 cells were used for 2D cultures. 50µl of the desired diluted 
drugs were added in a 3x concentration upon 48h to each well of the 96 well 
plates. Viability assays were performed for all samples upon 72h of treatments. 
Drug treatments for protein extraction required shorter incubation periods 
and final drug concentration met the correspondent IC30. 
 
2.6.1- Dose curve and IC50 
 
 Dose curves were based on the viability of cells, either on 2D or 3D 
cultures, upon 72h of drug treatments with gradual dilutions. CellTiter-Blue 
was used to measure 2D viability, whereas CellTiter-Glo was the preferred 
method for 3D cultures.  
 The percentage of viability was calculated against the DMSO control and 
values plotted on a graph with GraphPad Prism software. A non-linear 
regression with an equation for dose inhibitory response with four parameters 
was then drawn and the IC50 was determined with the displayed curve values. 
 
2.7- MEK inhibition resistance 
 
 3D cultures of LKR and D lines were treated for 10 days with a 
correspondent IC70 dose of the MEK inhibitor Trametinib. 50µl of Trametinib 
was added new every 3 days. 
 Trametinib survival cells were trypsinized and transferred to monolayer 
into 10cm petri dishes. Afterwards, cells were assayed again for Trametinib 
response in 2D and 3D cultures and IC50 determined as described in the 
previous subsection. 
 
2.8- KRAS knockdown spheres 
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 For all experiments cells were plated in the absence of antibiotics and 
usually cells were starved the day before with no serum.  
 siRNA was performed in 3 different ways: 
 
 1- Transfection took place at the same time as cells were plated into 3D 
cultures: 
 In this assay 2500 cells were used in 2.5% (v/v) matrigel. 
Oligonucleotides (siRNA KRAS pool, RISC-free and scramble) were used 
at 25nM as final concentration and DharmaFECTTM transfection reagent 
supplied by Dharmacon TM was used. 
 To do so, for each well, 2x solutions were made. 1µl of 5µM 
oligonucleotides was added to 9µl of DMEM and 0.4µl of DharmaFECT 
reagent was added to 9.6µl of DMEM. Both solutions were mixed and 
incubated for 20min at room temperature. Then 80µl of antibiotic-free 
normal media were added to a final volume of 100µl (solution A).  
 The preparation of cells in matrigel was also made with 2x 
concentrations. Thereby, for each well, 25ul with 2500 cells were mixed 
with 25µl of 10% (v/v) matrigel.  
 Finally, equal volumes of solution A and cells were mixed, plated 
and centrifuged (as described in section 2.1.5.1) to give 2500 cells in 2.5% 
(v/v) matrigel transfected with 25nM of oligonucleotides. 
 
 2- Transfection was made 2 days after platting cells into spheres: 
 In this case, 3D cells in 2.5% (v/v) matrigel were transfected with 
oligonucleotides for a final concentration of 125nM. 5µM siRNA stock 
solution and DharmaFECT reagent were used. Spheres were carefully 
washed with cold PBS to remove matrigel before transfected with 100µl. 
 
 3- Transfection was done in 2D cultures. 
 For this assay, 15000 cells were plated in 6 well plates for two 
days. Low confluence cells (30-50%) were transfected with 
OligofectamineTM reagent supplied by InvitrogenTM with 200nM of 
oligonucleotides as final concentration.  
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 To do so, for each well, 4µl of Oligofectamine reagent was diluted 
with 11µl of DMEM and incubated for 10min at room temperature. Then, 
40µl of 5µM stock oligonucleotides were diluted with 145µl of DMEM, 
mixed and incubated with the previous solution for 20min at room 
temperature. Finally 800µl of DMEM was added to the mixture and 1ml 
was poured into the cells. After 4h of incubation at 37ºC in 5% CO2, 
normal media with 3x FBS was added.  
 On the following day 2D transfected cells were transferred into 3D 
cultures as described in the procedure of section 2.1.5.1. 
 Lysates were collected after transfection from 2D and 3D cultures 
to confirm the efficiency of the procedure by qPCR. 
 Cells were monitored after 48h for viability with CTB assay. 
 
2.9- Data analysis 
 
 Data was in part analysed with Microsoft excel to determinate triplicate 
average, standard deviation, to subtract blank, calculate fold changes and 
viability percentages as well as to calculate new standard deviations 
accordingly to the analysis made. 
 Worked data was then plotted with GraphPad Prism which allowed the 
determination of several parameters. 
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Chapter 3 
 
 
Results and Discussion 
 
3.1- Design of a 3D culture method 
 
The first aim of this project was to develop a method that will allow the 
growth and survival of lung cancer cell lines into 3 dimensional conditions. For 
that purpose, seven different established cell lines of non-small cell lung cancer 
cells were used.  Six of them are established from NSCLC tumors with KRAS 
mutant and p53 deleted (KRASG12D/+; Trp53F/F; Rosa26mTmG/+ mouse 
model): B, D, F, E, MetA and MetB lines; the latter two coming from a 
metastatic site. The seventh cell line is LKR line that has been established from 
NSCLC with KRAS mutant but wild-type p53 (KRASG12D/+; Rosa26mTmG/+ 
mouse model). Additionally, all cell lines express the green fluorescent protein 
(GFP) apart from LKR. 
 
 3.1.1- Soft agar cultures 
 
 At the first place, a simple and fast method was used to check which cells 
would have a positive growth under non-anchorage independent conditions. 
 As described in the materials and methods section, cells were kept in soft 
agar plates for three weeks, generating agglomerates in only four cell lines: 
LKR, D, E and MetA lines (Figure 8). Sphere formation in these specific cell 
lines points for the existence of a bigger population of cancer stem cells (CSCs) 
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or tumour-initiating cells (TICs), which has been identified as a property of 
CSCs [4], [27].  
 
 
Figure 8. Non-anchorage independent cell growth is observed for certain NSCLC cell lines. 
End-point assay of soft agar cultures with 40000cells. Giemsa staining, on the upper panel, 
shows the formation of colonies after three weeks for LKR, MetA, D and E lines. The lower 
panel shows microscopic images of the corresponding soft agar plates.  
 
 This method has allowed us to identify LKR, D, E and MetA lines for 
future experiments. However, the use of this method is not ideal for automation 
and high-throughput screenings with drugs, explaining the further search for 
different non-adherent growth methods. 
 
 
 3.1.2- Non-adherent surfaces 
  3.1.2.1- Non-adherent round bottom plates 
 
Taking in account the previous results the following step was to test non-
adherent round surfaces with the cells that had grown in soft agar. This is an 
easy and straightforward method known to allow cell growth in suspension. 
Moreover, as had already been described before, the absence of serum had a 
positive impact on cell growth, which was also tested [27].  
The metastatic cell line MetB is used here as a negative control for the 
anchorage-independent growth. After one week, MetB does not form spheres 
when plated without serum. It appears with a scattered morphology composed 
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by some small agglomerates and some cells attached to the bottom of the plate. 
On the other hand, D and LKR lines, both in starvation and normal media 
conditions, showed a decrease in the diameter of the overall sphere. Moreover, 
the morphology indicates that the cells are fused together, but with an 
unhealthy appearance (Figure 9). Thus, although the use of non-adherent round 
bottom plates is an easy and fast method, it is not useful for our purposes. 
 
 
 
 
 
 
 
Figure 9. Cells form clumps and shrunk in non-adherent round bottom plates. D and LKR 
lines were cultured in the presence and absence of FBS serum in non-adherent round bottom 
plates, being monitored through 7 days. Microscopic images show a clear shrinking and 
unhealthy morphology upon 7 days. The negative control, MetB line which does not grow in 
soft agar, shown to be able to attach the plate and does not form clumps. 
 
 3.1.2.2- Non-adherent coated plates 
 
 Once the last results did not show satisfactory cell morphology after one 
week culturing, other simple methods were tested. The use of coated plates has 
already been described by several laboratories. Cells were seeded as stated 
above in material and methods on top of either 0.6% (w/v) agar or polyhema 
and followed for one week.  
 In both coatings cell growth was observed, and cells have a similar 
morphology to the negative control, line B. Agar 0.6% (w/v) allowed cells to 
form quite lose agglomerates which got more condensed over time. On the 
other hand, polyhema coated surfaces, shows a randomly formed tubular shape 
that seems to have packed together after one week for B and LKR cell lines 
(Figure 10).  
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Figure 10. Cells form clumps and appear with high levels of DAPI foci in non-adherent 
coated plates. MetA, B and LKR lines were kept in culture for 7 days in coated plates, either 
agar 0.6% (w/v) or polyhema. Microscopic images along with DAPI staining after 7 days 
(bottom row) indicates high levels of cell death. 
 
 For both coating systems, DAPI staining indicates that the amount of 
dead cells is significantly high, proven some degree of toxicity of these coating 
surfaces. 
 
 3.1.3- Hanging drops technique 
 
The hanging drop technique, as described in materials and methods, is 
used by many research groups with satisfactory cell growth results [52]. Tests 
with this method showed certain handling difficulties inappropriate for 
automated screens. However, culturing cells on an hanging drop appears to 
have an important role in the cohesion of cells and in shaping a sphere that 
remains intact for at least 7 days after transference into an agar coated well. 
 In overall, spheres shrink over time, appear darker and more compacted 
with an apparently more organized structural morphology (Figure 11). 
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Figure 11. Culturing cells in hanging drops allows its shaping and cohesion. Microscopic 
images of cells on top of agar after had been shaped overnight in 0.25% (w/v) methylcellulose 
hanging drops. Kept in culture for 7 days they shrunk but keep a stable aggregated 
morphology. 
 
 3.1.4- Matrix embedding (Extracellular Matrix 
Proteins) 
 
Since the previous results were not reasonable in terms of cells 
morphology, growth, survival and mainly due to the low applicability in high-
throughput screenings, other culture ways were tested. Embedding cells in a 
matrix has been shown to bring advantages for cell growth [27], [28]. It not only 
gives a physical protein support that mimics the extracellular matrix present in 
vivo tumors, but is also believed to provide some protein growth stimulus.   
Assays showed that embedding cells in different proteic components of the 
extracellular matrix gives rise to tumorspheres with different morphologies that 
change over time. Moreover, the type of embedding has an impact on sphere’s 
growth and survival. 
When cells are embedded in 0.25% (w/v) methylcellulose, cells show a 
scattered profile 24h after seeding. After one week, cells normally shrink into 
very compacted spheres, mainly lines D and B. At this stage line D contains 
several cells surrounding the main sphere, which might be an indicator of stress 
or death [53] (Figure 12). 
Matrigel is undoubtedly the matrix that produces the most rounded shaped 
and smooth spheres [4], [54]. In overall, whereas 5% (v/v) matrigel results in 
quite compacted spheres, 1% (v/v) matrigel generates looser aggregates of cells 
24h after seeding. After one week, spheres appear to have shrunk just for B line, 
while the others tend to keep the same diameter or eventually grow as happens 
with line D in 5% matrigel. Cells plated in matrigel 2.5% (v/v) acquire a similar 
morphology to the ones in 5%, losing the dispersed effect within 1% at 24h 
(Figure 12). 
Moreover, a closer analysis of the spheres through time lead to the 
conclusion that it is necessary at least 48h for the spheres to become stable in 
terms of size and compression (Figure 12). 
 
31 
 
 
 
 
 
 
 
 
 
Figure 12. Matrix embedding cells have a key role in shaping morphologically better and 
more compact spheres. Microscopic images of several cell lines were taken when cultured 
under different embedding conditions. The upper left set of images is taken as a control for 
growth in normal media. Clear morphologic differences can be observed especially when 
comparing the control with matrigel embedding spheres, that apart from the negative control B 
line, seem to have kept the same diameter and emerge well shapely defined without dispersed 
cells. The lower right panel describes the time evolution of MetA line in two different 
conditions, revealing the size stabilization upon 48h of culturing. 
 
Large-scale drug screenings with 3D models requires the automation of 
the system, which implies taking into account some robotic limitations. Among 
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them there is the refrigeration during the seeding, the use of only slightly 
viscous substances and the impossibility of removing reagents. In spite of the 
better appearance of cells within matrigel 5% (v/v), its viscosity is incompatible 
with the robotic system.  
 In this sense, the overall outcome of these assays have demonstrated that 
throughout the different available three dimensional culture methods, the one 
that brings better results regarding morphology, growth and ability to be used 
in large-scale drug screenings, are the cells growing in embedded matrix of 
2.5% (v/v) matrigel. 
 
3.2- Viability methods 
 
 Monitoring the viability of cells is one of the most important steps when 
doing drug assays. All the effectiveness of drugs is monitored by survival 
outcomes. This emphasizes the crucial importance of having a viability 
technique that can be as accurate and precise as possible and, at the same time, 
can allow the use of automatic systems for screen purposes. 
 Several methods were tested and compared between each other for 
different three dimensional culture systems. 
 
3.2.1- CellTiter-Blue assays 
 
 One of the most commonly used viability assay in 2D cultures is the 
celltiter-blue assay. Its fluorescent signal results from the reduction of resazurin 
into resorufin by the cell redox coenzyme NADH. The signal should therefore 
be proportional to the number of metabolically active cells.  
 However, the use of the same method on 3D cultures showed that this is 
not a valid test. Its sensitivity is very low which might be explained by a low or 
null penetration of the redox dye (resazurin) into the core of spheres, disabling 
its reduction into resorufin by metabolically active cells. When corrected against 
the blank, quantification of the fluorescent signal gives a negative signal that 
does not correspond to the real cells viability (Figure 13). 
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Figure 13. CellTiter blue viability assay is not sensitive to spheres. Reading resorufin 
fluorescence intensity on spheres cultured during 7 days gives a negative viability signal when 
corrected against the blank. This emphasizes the low sensitivity of the assay. 
 
3.2.2- CellTiter-Blue with EDTA treatment 
 
 Treatment of spheres with the quelant agent EDTA has been shown to 
cause the disaggregation of spheres into separated cells [53]. For this reason we 
tested this method that overcomes the lack of sensitivity of the CTB assay alone, 
showing a higher fluorescence intensity signals (Figure 14). 
 However, microscopic observation revealed that dissociation of spheres 
was still not completely efficient denoting possibly that this method was still 
not as precise as needed, being most likely a bit misleading with elevated 
fluctuations. In this sense, further viability methods were tested.  
 
 
 
 
 
 
 
Figure 14. CellTiter blue viability assay upon EDTA spheres disaggregation disclose better 
results. Spheres treated for 45min with 5mM EDTA are able to dissociate and give a higher 
fluorescence reading.    
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3.2.3- Trypan blue staining 
 
A routine method to quantify live cells is using the trypan blue staining 
with the cell counter, which was also used with spheroids (Figure 15). 
However, it is a quite tedious and manually laborious procedure that implies 
long incubations with dissociating agents leading to low accurate and 
misleading results. 
Comparison of the relative values between this method and the one shown 
above with CTB plus EDTA for the same experiment showed no correlation 
(Figure 14, 15). Contrarily to CTB, trypan blue staining gives a positive growth 
only for LKR in 5% (v/v) matrigel, 1% (v/v) matrigel and for the control in 
suspension with normal media, as well as for MetA and D lines when growth 
takes place exclusively in 5% (v/v) matrigel. This invalidates CTB plus EDTA 
method that gives a high signal for many more conditions and cell lines. 
 
 
 
 
 
 
Figure 15. Viability tests with trypan blue staining do not correlate with CTB + EDTA 
results. The number of live cells is represented for different culturing methods and was 
measured with trypan blue that stains for dead cells. The overall outcome is not comparable 
with other viability tests invalidating those assays. 
 
3.2.4- Integrated density of the GFP fluorescence 
 
As described before, almost all the used cell lines are GFP positive, 
meaning that spheres size can be monitored along the GFP intensity signal, 
which should correlate with the viability of cells. Hereby, the product of the 
area and the mean gray pixel value of the GFP signal over DAPI stained images 
should give a proportion of alive cells in the sphere. Results emerge with line D 
having the highest integrated density for 5% (v/v) matrigel, followed by line 
LK
R
M
et
A D B
0
5000
10000
15000
N
u
m
b
e
r 
o
f 
c
e
lls
Matrigel 5%
Matrigel 1%
Methylcellulose 0.25%
Suspension
Live	cells	per	sphere	(Tryphan	blue	staining)
35 
 
MetA, which bring some inconsistency regarding the previously described 
assays.  
Most likely, this disparity may have arisen from the size and density 
variation of the cells over time, ending up with a higher intensity value over a 
smaller area, for example, fact that does not necessarily correlates with the 
amount of dead cells. This can be confirmed by the positive control for cells 
treated with staurosporin, a very toxic agent, which showed a dose dependent 
increase of DAPI signal, but an almost constant GFP signal (Figure 16). This 
indicates that the GFP fluorophore in spite of being produced only in living 
cells, is still active in dead cells, being able to re-emit light upon light excitation. 
Moreover, this is not a simple method and cannot be used in large scale 
screenings. It requires a manual long analyses of each individual image as 
described in materials and methods. Thereby, due to the misleading results of 
this method, which shows a stable GFP signal upon cell death, a low 
connotation must be attributed to this kind of assay. 
 
 
 
 
 
 
 
 
Figure 16. Total GFP integrated density measurement is an unhandy and misleading 
viability method. A. Total GFP integrated density of spheres cultured in 5% (v/v) matrigel. B. 
Cell death induced with staurosporin on MetA 5% (v/v) matrigel spheres. Whereas DAPI 
signal increases, GFP remains stable. 
 
3.2.5- Acumen - GFP fluorescence signal 
 
 Large-scale screenings with monolayer cultures are usually monitored by 
the confluence of cells that gives a growth ratio regarding the control. Attempts 
to use this same method were made taking into account another functionality of 
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the same used machine: the automatic measure of the spheres area based on its 
intrinsic fluorescent GFP signal (Figure 17). 
However, as happens with the integrated density measurements, the same 
problem arises due to sphere area variability, producing a high susceptibility 
for misleading results and low reliability.  
 
 
 
 
 
 
 
Figure 17. Total sphere area measured by acumen based on GFP signal is variable and 
misleading. A. Total sphere area for 2500 loading cells in matrigel 2.5 and 1% (v/v). B. Sphere 
area for different cells loading on matrigel 2.5% (v/v). There is an increase in area but the 
variability is high. 
 
3.2.6- CellTiter-Glo assay 
 
Viability tests relying in morphologic characteristics of the cells, as is its 
size, displayed some disadvantages. In this sense metabolic assays should be 
more reliable. However, the tested methods, such as CTB, have also shown low 
accuracy.  
Some assays are now available in the market specially designed for 3D 
cultures. One of the available methods, the CellTiter-Glo is a luciferase based 
assay that measures the quantity of ATP available inside the cell, that should be 
proportional to the number of live cells. Its lysing properties enable it to 
penetrate efficiently the core of the spheres increasing the sensitive of the assay, 
turning the readout more realistic and informative.  
Apart from the better sensitivity of this assay, and the removal of the most 
of the bias from the other tested assays, this is a very simple end-point method 
that can perfectly be used in large-scale screenings in an automatic way.  
Furthermore, the intensity of the signal is good, the variability is acceptable and 
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it shows a good proportional correlation with the number of plated cells (Figure 
18). 
 
 
 
 
 
 
 
 
Figure 18. CellTiter-Glo viability assays shows high spheres sensitivity and low variability. 
A. Total fluorescence intensity for 2500 loading cells in matrigel 2.5 and 1% (v/v). B. Spheres' 
luminescence signal for different cells loading on matrigel 2.5% (v/v). Luminescence is directly 
proportional to the number of plated cells. 
 
 Regarding all the tested viability assays and for the reasons mentioned 
above, CellTiter-Glo is undoubtedly the most reliable one, and so it was chosen 
for the following assays. 
 
3.3- Outlook – viability of 3D culture 
 
A drug screen with spheroids brings certain limitations that need to be 
overcome. Experimental design needs to be ensured for each different cell line 
to guaranty the reproducibility of the assay. Hereby, a standardized protocol 
with a consistent spheroid size needs to be taken into account as well as the 
microsatellites often observed in 3D cultures need to be discarded. This will 
reduce the variability of the tests and bring more accurate results with better 
analysis. Spheres size variability implies different core oxygenation and 
nutrient uptake, resulting in different gradients generally similar to in vivo 
tumors [55]. These oscillations also establish protein expression levels and 
proliferation rates, which are expected to result in different therapy responses 
comparing to 2D drug screenings [28]. 
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 In this sense, setting up the best conditions to culture cells in a three 
dimensional way compatible with drug large-scale experiments, needs to be 
easy to handle, be very consistent, ensure cell growth and survival through at 
least one week and finally its viability needs to be accurately monitored.   
 For this reason, it was then important to test again the different 3D 
culture methods with the CTG assay and evaluate cell growth over time (Figure 
19). 
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Figure 19. Embedding spheres in matrigel express the higher cells' survival and growth rates 
over one week. Linear graphs show 1 week fold change luminescence for lines D and MetA 
cultured under different methods for variable cells loading. Bar graphs show the viability fold 
change for the different methods over one week for a fix cell number. Matrigel shows the best 
results with positive growth after one week.   
 
As already seen in the previous assays, the outlook from the viability in the 
course of 1week throughout the different 3D culture plating techniques, points 
out how matrigel has a clear importance on the growth and culture 
maintenance of the NSCLC MetA and D lines.  
These results discard the use of methylcellulose as a successful matrix for 
long-term cell growth as well as the hanging drop. Having in consideration the 
robotic limitations for large-scale screenings and the outcome from the analysis 
of the different techniques, 2.5% (v/v) matrigel appears as the best option. 
Apart from the 3D methodology, consistency cannot be reached without 
the determination of the best cell loading. CTG oxyluciferin fluorescence signal 
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shows to be dependent on the amount of seeded cells. Line D is a good model 
on how the curve slope tends to be bigger for the lowest amount of cells, 
stabilizing above 2500 cells. Cells maintained in 5% (v/v) matrigel show a 
viability decrease between 48h and 96h after plating, recovering considerably 
after one week on both tested cell lines, MetA and D. This decrease can be 
associated with a natural selection for the most non-anchorage dependent cells, 
allowing them to start growing much more afterwards (Figure 20). 
 
 
 
 
 
 
 
 
Figure 20. Luminescence is mostly proportional to a cell loading bellow 2500 cells. Variation 
of luminescence through time according to the number of plated cells in matrigel 5% (v/v). A 
stabilization of the luminescence signal is observed above 2500 cells mainly for D line. 
 
In this way, 2500 cells seem to show the best results. The saturation of the 
system is avoided and drug tests are more likely to work, generating more 
trustworthy results. Cells will have around 300µm of diameter, forming a 
gradient of nutrients and oxygen, that is observed in vivo tumors, allowing at 
the same time drugs to penetrate the core, eliminating possible false negatives 
in drug screenings.   
 
Altogether the described results have defined the best conditions to be used 
for all the following experiments. 2500 cells need to be seeded in 2.5% (v/v) 
matrigel and drug assays should be started after 48h. Ultimately, viability of 
cells should be monitored with CTG assays.  
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3.4- Morphology of the spheres 
  
 The all purpose of growing cells in a three dimensional way, lays on the 
total surface interaction between cells alike the in vivo situation. The 
morphology of cells was analyzed by several resources to understand the 
general organization of the spheres and to get further insights about the 
existence of connections between cells.  
 
3.4.1- Transmission electron microscopy (TEM) 
 
The spatial organization of the spheres was monitored by TEM either after 
48h or one week upon seeding. Cells in 3D cultures display a very healthy 
morphology, with normal organelles, especially plenty of mitochondria, golgi 
apparatus and lysosomes (Figure 21A). 
Indeed, in one week, structural modifications and connecting interactions 
are evident especially in D line spheres. It shows a curious particular 
phenotype: Cells differentiate into other cells with different organelles and 
structures, that may be important for nutrient uptake; they specifically form 
structures similar to acini characterized by the presence of microvilli cells with 
tight junctions only at the top of the cells facing the lumen of the acinus; gaps 
are certainly fulfilled with matrix secreted by these microvilli cells, probably 
playing a role on their survival; Numerous linkage structures like adhesion 
junctions and desmosomes are also present (Figure 21). 
This interesting organizational fact is just present in 3D culture, whereas in 
2D they have just cells with very short and rare microvilli (Supplementary 
Information 1). This denotes the exclusive potential of 3D culture cells to 
differentiate and change its structural organization. 
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Figure 21. TEM images for D line. A. D line shows an healthy morphology and organelles 
anatomy. With lysosomes, mitochondria and golgi very often observed. B. Gap filled with 
matrix secreted from cells. C. Adhesion junction D. Desmosome on top of the cells facing the 
acini lumen. E. Acini. F. Long microvilli facing the acini lumen. 
 
The scenario changes for the other cell lines. On B line, cells are tightly 
packed but arranged randomly. It is very difficult to see junctions between cells, 
just cell-to-cell contacts. There are no tight junctions, no villi and the presence of 
desmosomes is dubious (Figure 22). On the other hand, LKR line shows lots of 
gaps between cells and no arrangement into structures. There exist lots of short 
villi that are probably just random protrusions from cells. There are cell-to-cell 
adhesions at random places but little tight junctions are observed. The 
occurrence of desmosomes is also not clear (Figure 23). MetA line that was 
screened 48h after seeding has many gaps between cells but no villi. There are 
adhesions at random places but it is hard to find junctions as well as 
desmosomes (Figure 24). 
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Figure 22. TEM images for B line. A. Tightly packed and randomly arranged cells. B. A 
possible desmosome. 
 
 
 
 
 
 
 
 
 
 
Figure 23. TEM images for LKR line. A. Many gaps between cells. B. Short microvilli. C. 
Adhesion junction seems to appear in random places. D. A possible desmosome. 
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Figure 24. TEM images for MetA line. A. Gaps between cells. B. Adhesion junction. C. 
Randomly placed adhesion junction. D. Desmosome 
 
3.4.2- Electron microscopy (EM) 
 
For an external point of view spheres were also examined by Electron 
Microscopy (EM). They all look very well packed together and surrounded by 
fibers of matrigel. The outer layer has a very smooth appearance and cells are 
completely linked to each other. Lines D and LKR are completely covered with 
micro-protrusions whereas MetA line is totally covered by matrigel, which 
makes the surface analysis more difficult (Figure 25). 
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Figure 25. EM images of D, MetA and LKR spheres.  Spheres appear very well packed and 
surrounded by matrigel fibers.  
 
3.4.3- H&E and E-cadherin marker 
 
 TEM and EM microscopy gave an overview of the structural 
organization of the cells, but to better understand how exactly cells are ordered 
within the sphere, E-cadherin expression pattern was also analysed by 
immunohistochemistry. Haematoxylin and eosin (H&E) staining was used as a 
control. 
E-Cadherin staining is positive for D and LKR lines, revealing cell 
differentiation and organization. D line forms acini E-Cadherin positive inside 
the sphere, as was already observed by TEM, whereas LKR as a strong positive 
signal just in the apical surface. H&E staining also shows in pink that in D line 
gaps are filled with some extracellular matrix secreted by cells. This means that, 
contrarily to LKR, line D lay down on its extracellular matrix. E-Cadherin is 
negative for MetA line, possibly justified by its metastatic derivation, with 
higher invasive potential (Figure 26).  
 Similar results were already published by Vertrees et al on BZR-T33 lung 
cell line (H-ras transfected BEAS-2B). Here, 3D cultures showed a higher degree 
of differentiation and marker expression more closely related to cells grown in 
situ, when compared to monolayer cells [25]. 
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Figure 26. H&E and E-cadherin staining.  H&E can be seen on the left side for the different 
spheres and on the middle and right side immunohistochemistry staining for the cell adhesion 
protein E-cadherin is demonstrated. 
 
Morphologic analysis of the spheres cultured in 2.5% (v/v) matrigel, 
showed a curious phenotype for D line, with evident differentiation upon only 
one week culturing, forming acini E-cadherin positive. Lines MetA and LKR are 
not as well organized as D line, but these ones still connect with each other 
through junctional complexes such as adhesion junctions and desmosomes. As 
expected, MetA cell line does not present the E-cadherin marker most likely 
because it is a metastatic line, and it is known that loss of this marker can 
increase the invasiveness potential of these cells [56].  
 
Altogether, the morphologic analyzes of the spheres had shown that, in 
general, spheres tend to form connections between each other. All the analyzed 
cell lines appear to have adhesion junctions. It indicates that spheres might 
indeed work and function as a multicellular organoid, swapping signals, 
stimulus and some factors. D line showed particular features, it is able to 
activate some differentiating functions, showing a very organized structure, 
with acini, microvilli. It is also E-cadherin positive for the cells facing the lumen 
of the acini and for the cells facing the apical side of the spheres. 
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3.5- Signalling Pathway 
 
Cells display morphologic differences depending on the way they are 
cultured. Addressing now whether these differences imply any impact on the 
activity of KRAS signalling pathway becomes a focus of importance.  
Indeed, when checking for the levels of Akt, Erk and MLC activation, all 
enrolled at the RAS protein cascade, there is a major difference in the levels of 
p-Erk that are twice higher in 3D cultures when comparing to 2D (Figure 27). 
Erk activation is known to be related with the higher potential of proliferation 
[57]. The Western-blot results indicate that cells growing in 3D either from a 
metastatic cell line as MetA as well as the KRAS mutant p53-/- D cell line, are 
more predisposed to proliferate. On the other hand, there is no difference 
between 2D and 3D cultures for p-MLC levels, which are known to be involved 
in cells motion [58]. Cells in 3D cultures tend to be confined to a single and 
unique sphere, they may be able to grow in volume and density, but usually the 
previous results gives the impression that they hardly grow in size, mainly 
when the number of loaded cells is superior to 2500. These results indicate that 
cells are as prone to move in 3D as they are in 2D cultures (Figure 27). 
Regarding the levels of p-Akt, there is no correlation between the two 
culture methods and the differences are not significant, being the Akt activation 
very low. p-Akt is an indicator of cell surviving and nutrient sensing [59]. 
Results indicate that most likely cells do not rely on p-Akt signalling pathway 
(Figure 27). 
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Figure 27. Differences in the signalling pathway between 2D and 3D cultures. Whereas Akt 
and MLC activation levels remain quite consistent for both culture methods, p-Erk levels tend 
to be increased in 3D cultures for MetA and D lines. 
 
 Results suggest that 3D cultures tend to have the MAPK pathway more 
active because of the higher levels of p-Erk.   
 
3.6- KRAS sensitivity – 2D vs 3D 
 
After the determination of the best conditions required to grow spheroids 
from NSCLC an interest to further investigate different sensitivities towards 
targeted therapies arose. We have shown that cells grown in 3D show 
morphological differences as well as variations in the expression levels of 
certain proteins compared with 2D cultures. There are also reports in the 
literature showing that 3D cultures tend to simulate more accurately the gene 
expression profiles in clinic, as well as the pathophysiological milieu in cancer 
patients demonstrating closer therapy responses. This may in turn improve 
clinical efficacy prediction of therapies, revolutionizing antitumor screening 
operations [27], [28].  
In this sense, it becomes essential to test the efficacy of chemical 
compounds known to interact in the oncogenic KRAS signalling in order to 
predict its outcome in a more realistic culture method that are 3D platforms, 
analyzing whether major differences can be found between the two culture 
systems. 
 
3.6.1- Preliminary drug screen 
 
Published data already reported that 3D cultures are expected to work in 
two ways: some drug candidates may lose efficacy in 3D assays, discarding 
further animal tests and eventually pull up its optimization; and others may 
exclusively be effective in 3D cultures. 
In this way, 3D drug screenings can indicate which chemical compounds 
should be followed up for later trials because of its potential to better estimate 
in vivo antitumor efficacy [28]. 
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A preliminary 3D drug screen was then made in MetA cell line using a 
kinase inhibitor library. Results obtained were analyzed and compared with a 
previous screen done in the host lab in 2D cultures with another cell line. 348 
compounds were used in a 10µM concentration as single replicates. Total 
sphere area was monitored by its intrinsic GFP fluorescence signal through a 6 
day period following treatment.  
A massive sphere area variability is observed in the control samples, 
mainly at day 6, whereas pretreated cells have minimal variations. Moreover, a 
72h drug treatment shows a smaller variation in regard to a 6 day treatment. 
This is certainly explained by the different growth rates brought up through 
time by minimal loading errors, the presence of misleading microsatellites or 
even by differences in the growth conditions within the same 384 well plate. 
These results highlight the complexity in the standardization of the 3D 
procedure even after consistent results in small scale assays (Figure 28). Data 
was selectively analyzed taking into account the viability range of positive and 
negative control drugs, and upon categorization into drugs with cytostatic, 
cytotoxic and growth effects, 10 hits were identified. Such hits were exclusively 
drugs which performed opposite effects regarding 3D and 2D cultures, failing 
to show efficacy in 2D and being highly efficient in 3D (Table 1). 
It is worth pointing that 2D data were extracted from a total independent 
experiment with a different cell line. A priori, it is known that this comparison 
can mask some potential effective drugs and can lead to contradictory results 
once done with the same cell line. The screen was done in the high-throughput 
screening facility with the objective of determining if the method could be 
automated and used in a high throughput fashion. Although we can take some 
information from it, ideally we should repeat it using at least triplicates for each 
point and comparing at the same time the 2D and 3D cultures.   
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Figure 28. Preliminary screening variability on MetA.  The left chart represents the spheres' 
size variability just for the untreated spheres over time. A variability range of about 10.000µm2 
is reach on day 6. The right chart shows the comparison of size variation between treated and 
non-treated spheres. Each dot represents one single sphere treated with one of the 348 used 
compounds with respective control sphere upon 72h and 6 days of treatment.  
 
 
Table 1. Top 10 hits identified after screening. From the kinase inhibitors library, 10 
compounds shown to be effective on 3D MetA cultures. Whereas, on an independent 
experiment with a different lung cancer cell line cultured in 2D, the same ones had a growth 
effect. 
 
Compound Description 
Day 6 - Viability fold 
change % (3D – MetA) 
Viability fold 
change % (2D) 
Gš 6983 PKC inhibitor -100 109.8 
IKK-2 Inhibitor VIII IKK-2 inhibitor -100 88.9 
TGF-β RI Inhibitor III 
Inhibitor of ACTR-IB, TGF-β RI and 
ACTR-IC -100 85.2 
Indirubin-3′-monoxime GSK-3β and CDK inhibitor -84.8 51.2 
GSK-3β Inhibitor XII, TWS119 GSK-3β inhibitor -65.8 55.1 
LY 294002, 4'-NH2 
PI3K inhibitor (p110α, p110β, 
p110δ, and p110γ subunits) -44.5 88.0 
Isogranulatimide ChK1 inhibitor -44.2 96.7 
IKK-2 Inhibitor IV IKK-2 inhibitor -38.3 44.0 
Compound 56 
Inhibitor of the tyrosine kinase 
activity of the EGF -32.3 74.5 
PI 3-Kα Inhibitor IV PI 3-kinase family inhibitor -31.0 54.1 
 
Taking into account the best drug candidates from the preliminary screen, 
further tests were done at small scale comparing the same cell line in 2D and 3D 
cultures (Figure 29). Cell viability was monitored with CTG assay 72h and 6 
days upon treatment. D line revealed to be quite sensitive for all drugs 
disregarding the culture method. The exception lays on the PD0332991 
dihydrochloride (CDK inhibitor), that upon 6 days of treatment showed a 
significant increase in the viability levels for 2D cells but not 3D, indicating that 
2D cells are less sensitive for this inhibitor. On the other hand, MetA line did 
not follow the expected pattern from the screening. It rather showed a better 2D 
effectiveness for BMS-345541 (IKK-β inhibitor) and Gö7874 (PKC inhibitor) 
drugs. PD0332991 dihydrochloride treatment had the expected effect, however 
not as strong as the screen. 
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Results showed that there are differences between 2D and 3D, but that 
these differences also differ between both cell lines. The exception is the CDK 
inhibitor that has the same response on MetA and D lines. Therefore, there is a 
need to generate uniform spheroid fractions to reduce variability [28], [60]. 
 
 
 
 
 
 
 
 
 
Figure 29. 2D and 3D viability upon treatment with 5 of the best drug candidates from the 
screen. 6 days of treatment with the CDK inhibitor PD0332991 dihydrochloride had a big 
impact on 3D cells viability for D and MetA lines whereas a considerable growth was observed 
for 2D cultures in both cell lines. 
 
Results with the most divergent viability percentages in both cell lines were 
then followed up to dose response assays with respective IC50 determination 
for both culture methods (Table 2). 
Dose curves follow different patterns. IKK-β inhibitor forms bigger slopes 
on 3D cultures, but the IC50 does not diverge significantly. However, at the 
highest drug concentrations, cells tend to reach the same levels of viability, 
being therefore affected by the same range of death (Figure 30). 
Previous reports had demonstrated that effectiveness of IKK-β inhibitors on 
KRASG12D induced lung cancers, is higher when they are tumor suppressor 
p53 deleted [17]. Assays are according to literature showing a high effectiveness 
on MetA and D lines but not LKR, which is KRAS mutant alone. For all cell 
lines, 2D showed to be a more sensitive culture model.  
Looking at the IC50 values along with the graphics, differences can be 
observed between 2D and 3D cultures with the PKC inhibitor Gö7874. LKR and 
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D lines are much more sensitive to this inhibition when cultured in monolayers, 
being spheres modestly more resistant. 
 
Table 2. IC50 values for IKK-β, PKC and CDK inhibitors on 2D and 3D cultures. LKR and D 
2D cells are significantly more sensitive to the PKC inhibitor Gö7874 than 3D cultures. NA 
means that cells did not reach IC50. 
 
  MetA LKR D 
Name Description 2D 3D 2D 3D 2D 3D 
BMS-345541 (µM) IKK-β (IKK-2/IKBKB) inhibitor 0.6 1.1 1.6 2.3 1.2 1.4 
Gö7874 (µM) PKC inhibitor 0.25 0.3 0.25 1.2 0.7 2.6 
PD0332991 
dihydrochloride (µM) 
CDK inhibitor - high selectivity 
for CDK4 and CDK6 
1.7 1.1 0.7 NA NA 7.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Dose effect of IKK-β, PKC and CDK inhibitors on 2D and 3D viability upon 72h 
treatment. Different responses can be observed between 2D and 3D cultures mainly for the PKC 
inhibitor Gö7874 and the IKK-β inhibitor BMS-345541. 
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Results obtained show that PKC inhibitor can produce more pronounced 
differences between the two culture methods, being quite more effective to 2D 
cultures whereas 3D cells acquire a certain resistance. This demonstrates that 
the efficiency of some drugs can vary depending on the growth conditions. 
 
3.6.2- KRAS target drugs 
 
As it was detailed before, cancer arises when normal growth regulation 
breaks down. RAS proteins are key regulators of cell growth controlling 
signalling pathways. RAS oncogene is capable of redirecting input signals to 
alternative pathways. This constitutively activates certain pathways, leading to 
higher amounts or high functional activity of transcription factors. Direct KRAS 
therapies have brought poor effectiveness. Additional mutations, either 
upstream or downstream of the pathway turned out to bring poor clinic 
prognosis [10], [16]. In this sense, targeting novel proteins involved in the 
process becomes crucial.  
Thus, a set of inhibitors known to be effective in 2D cultures was used at 
this time also in 3D cell models in an attempt to find different vulnerabilities 
between 2D and 3D cultures for RAS mutant cells. 
 
3.6.2.1- MEK and PI3K inhibitors 
 
Cells are strongly sensitive to MEK inhibitors both in 2D and 3D without 
major differences between methods apart from LKR cell line, which clearly 
showed to be less sensitivity in spheres (Figure 31). 
PI3K inhibitors were also used to block AKT/PI3K parallel pathway, 
known to be activated by RAS. Indeed, they were effective for all tested cell 
lines (Figure 31). Although, major differences were noticed between 2D and 3D 
methods on D line, that comes with a lower IC50 for 3D cultures indicating 
higher sensitivity of these cells. These results can be supported by morphologic 
reasons. Line D survival might rely on external stimulus [21] that propagate 
much better when cells are closely pack together with a bigger membrane 
surface. On the other hand, LKR and MetA appear to be more sensitive to PI3K 
inhibitors on 2D cultures, with an IC50 four times lower for MetA (Table 3). 
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Figure 31. Dose effect of MEK and PI3K inhibitors on 2D and 3D viability upon 72h 
treatment. Clear different responses can be found between culturing methods for MEK inhibitor 
Trametinib in LKR line and PI3K inhibitor GDC941 in D line. 
 
Table 3. IC50 values for MEK and PI3K inhibitors on 2D and 3D cultures. LKR 2D cells are 
more sensitive to Trametinib. GDC941 brings more sensitiveness for 2D MetA cells and 3D D 
line cells. 
 
IC50  MetA LKR D 
Name Description 2D 3D 2D 3D 2D 3D 
Trametinib (nM) MEK inhibitor 0.5 0.6 0.3 43 1 0.4 
GDC941 (nM) PI3K inhibitor 1040 4000 220 460 1560 225 
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These results bring to light that the LKR line is less sensitive to the main 
pathway MEK and PI3K inhibitors when cultured in spheres. PI3K inhibitor is 
more effective on 3D cultures for the D line, but the opposite happens for MetA, 
indicating a cell line response dependency. Once more we see here that 
differences between 2D and 3D do exist, but they are dependent on the cell line. 
 
Taking into account the different sensitivities upon MEK inhibition, the 
respective signalling pathways were analysed (Figure 32). The reduced levels of 
p-ERK upon treatment indicate that Trametinib is working on spheroids. P-ERK 
is not detectable on non-treated 2D cells, but increasing levels of p-MEK after 8h 
treatment confirms a positive feedback loop due to MEK inhibition. 
Conclusions about the different sensitivities between 2D and 3D cannot be 
made with this western blot assay, once it does not display major differences 
between both cell lines and the signal for p-AKT was too low. However, the 
lower levels of NF-kB upon 8h treatment of D line in 3D may be responsible for 
the higher sensitivity of these cells towards Trametinib, as it is also confirmed 
by its lower IC50. The D line is then probably relying more on NF-kB pathway 
when it is cultured in 3D conditions.  
 
 
 
 
 
 
 
Figure 32. Effect of MEK inhibitor on signalling pathway for 2D and 3D cells over time. 72h 
upon treatment with the correspondent IC30 dose, lysates were blotted against the indicated 
proteins. As expected, Trametinib is having an effect on p-ERK levels but no differences 
between D and LKR lines are able to explain the observed different drug sensitivities. NF-kB 
(p65) levels are shown for D line. The decreasing levels upon 8h for 3D cultures indicate a 
higher dependency of this type of cultures from this signalling pathway. 
 
Further studies are needed in order to understand how differently these 
inhibitors may affect the pathway accordingly to cells morphology and spatial 
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disposition. Therefore, western blot optimization along with a more efficient 
sphere protein extraction is required to achieve detectable p-AKT levels. 
 
3.6.2.2- Other inhibitors 
 
Proteasome inhibition by Bortezomib, a drug already used in clinic, is 
totally effective with minimal doses and no major differences were found 
regarding the culture method used (Figure 33, Table 4).  
 
 
 
 
 
 
 
 
Figure 33. Dose effect of proteasome inhibitor Bortezomib on 2D and 3D cells viability upon 
72h. Bortezomib appears to be very effective even for minimal concentrations. 
 
The IKK-2 inhibition outcome from the preliminary screen, and the abrupt 
viability drop observed just in 3D cultures, enhanced the curiosity for the use of 
other chemicals targeting the same pathway. But, in fact, the use of IKK2 
inhibitor VIII had no impact on cells even at higher doses than the 
commercially recommended to reach IC50 (Table 4). 
 
The effects of other drugs were addressed and unexpectedly many of them 
had no effect on the viability of cells either on 2D and 3D models (Table 4). 
 TGF-β inhibition had little effect on cells independently of the cell culture 
method. This is possibly because of the presence of many other GTP-RAS 
stimulators that assures the persistent activation of downstream pathway 
leading to deregulated proliferation and cell survival.    
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Dose curve analysis for LDH-A inhibitors shows no effect on 3D MetA and 
D lines, which indicates a possible absence of an hypoxic core. 
c-Met inhibitors had no effect either on 2D or 3D cultures, emphasizing that 
not all of the KRAS mutant cell lines rely on Met to overcome the Anoikis 
process. Literature does not focus on metastatic cells lines, but reports also fail 
to show Met dependency for MetA line [46]. 
Rho inhibition on MetA and D lines did not have any effectiveness on both 
2D and 3D cultures. Confluence of 2D cells and 3D closed organization may 
constrain the Rho signalling dependency of these cells, explaining the lack of 
efficacy for these inhibitors in KRAS mutants.  
 Moreover, further assays also showed no efficacy or either 2D vs 3D 
differences towards Focal Adhesion Kinase (FAK) inhibitor compounds.  
 
Table 4. IC50 values for several inhibitors on 2D and 3D cultures. Little effect could be seen 
with most of the used inhibitors. Bortezomib easily lead to cells' collapse and no significant 
differences were observed between 2D and 3D cultures.  NA means that cells did not reach IC50. 
(-) means that the assay was not performed. 
 
IC50  MetA LKR D 
Name Description 2D 3D 2D 3D 2D 3D 
Bortezomib (nM) Proteasome inhibitor 0.1 0.1 0.1 0.2 0.2 0.3 
IKK2 inhibitor VIII (nM) IKK-2 inhibitor NA NA - - NA NA 
SB-505124 (µM) TGF-β inhibitor NA NA NA NA NA NA 
PF562271 (nM) FAK inhibitor NA NA NA NA - - 
GSK2837808A (nM) LDH-A inhibitor NA NA NA NA - - 
CT04 (µg/µl) Rho inhibitor NA NA - - NA NA 
PHA665752 (nM) Selective and ATP-competitive 
inhibitor of c-Met 
NA NA NA NA NA NA 
PF-02341066 (nM) c-Met and ALK inhibitor NA NA NA NA - - 
 
 Results obtained demonstrated no viability differences between 2D and 
3D culture methods. This indicates that for all these tested inhibitors there are 
no strong evidences that using 3D cultures can bring further insight about the 
outcome in in vivo systems. 
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3.6.2.3- Structural stability inhibitors 
 
The pathway complexity involved in KRAS cancer cells and the negative 
feedback loops able to compensate the signalling highlight the difficulty on 
finding a successful therapeutic target.   
A different approach was taken using inhibitors that may alter the 
structural stability of cells. The main characteristic of cancer cells 3D cultures is 
the overall arrangement similar to in vivo tumors. Thereby, disturbing this 
organization is expected to be more harmful for 3D cultures than 2D. The actin 
assembly inhibitor Latrunculin had indeed a good effect on LKR and MetA 
viability cell lines, being the first one quite sensitive especially when cultured as 
spheroids, whereas monolayer treatment did not reach the IC50 (Figure 34). 
A similar effect was encountered with Paclitaxel, a tubulin polymerization 
promoter and stabilizer already used in clinic. Very promising results were 
achieved for MetA cell line, with positive 3D sensitiveness disregarding the 
cytostatic effects on 2D cultures (Figure 34). Such difference cannot be found for 
LKR and D lines which indicates a cell line-dependent drug sensitivity  (Table 
5). 
The half-life of these compounds may also play an important role on the 
outcome of these end-point assays, and once its effects were just monitored 
upon 72h treatments, resistance and recovery is likely to happen. 
 
 
 
 
 
 
 
 
Figure 34. Dose effect of Paclitaxel and Latrunculin on 2D and 3D viability upon 72h 
treatment. A clear different response is observed for MetA line when treated with the tubulin 
stabilizer. While there is a drop on spheres viability, 2D cultures are not affected. Similar effect 
can be seen for LKR with the actin inhibitor. This cell line is more sensitive in 3D than 2D 
cultures.  
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Table 5. IC50 values for Paclitaxel and Latrunculin on 2D and 3D cultures. MetA 3D cultures 
are significantly more sensitive to Paclitaxel then 2D. LKR 3D also shows a lower IC50 towards 
Latrunculin treatment. NA means that cells did not reach IC50. (-) means that the assay was not 
performed. 
 
IC50  MetA LKR D 
Name Description 2D 3D 2D 3D 2D 3D 
Paclitaxel (nM) Tubulin polymerization 
promoter and stabilizer 
NA 3 NA NA NA NA 
Latrunculin (nM) Actin assembly inhibitor 155 90 NA 55 - - 
 
 Results obtained indicate that inhibitors that interfere with cell structure 
are more successful in 3D cultures. The spatial cell organization has then an 
important role in the effective response of these inhibitors. 
 
 In general, these preliminary assays showed that 2D and 3D drug 
responses are cell line dependent. Differences between culture methods are not 
clear for several of the tested inhibitors. Only the D line, when cultured under 
3D, appears to be more sensitive to inhibitors that target effector proteins of the 
KRAS pathway. Interestingly, this is the only cell line that showed 
differentiation functions and a very organized structure. For the other two cell 
lines, LKR and MetA, differences can only be observed with structural 
stabilizing inhibitors, which have a big impact in 3D cell viability (Table 6). 
 This demonstrates the importance of exploring in future work the impact 
of cells organization and stabilization in cell survival. Moreover, it is also 
important to bear in mind that cell organization and differentiation affects the 
way cells react towards pathway inhibitors, as can be observed with the D line.  
 
Table 6. Overview of the culture method that confers the highest sensitivity towards the 
corresponding drug. 3D cultures for D line confer more sensitiveness upon inhibition of 
proteins involved in the signal transduction. 3D cultures for MetA and LKR just have a bigger 
impact on viability with structural stabilizing inhibitors. NA means that cells did not reach IC50. 
ND means that there are no differences between 2D and 3D. * means that the difference 
between 2D and 3D is not very significant, the highest IC50 divided by the lowest IC50 is less 
than 2. 
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Higher sensitiveness   
Name Description MetA LKR D 
BMS-345541 (µM) IKK-β (IKK-2/IKBKB) inhibitor 2D 2D 2D* 
Gö7874 (µM) PKC inhibitor 2D* 2D 2D 
PD0332991 
dihydrochloride (µM) 
CDK inhibitor - high selectivity 
for CDK4 and CDK6 
3D* 2D 3D 
Trametinib (nM) MEK inhibitor 2D* 2D 3D 
GDC941 (nM) PI3K inhibitor 2D 2D 3D 
Bortezomb Proteasome inhibitor ND 2D 2D* 
Paclitaxel (nM) Tubulin polymerization 
promoter and stabilizer 
3D NA NA 
Latrunculin (nM) Actin assembly inhibitor 3D* 3D NA 
 
3.6.2.4- KRAS sensitivity to combined targeted therapies 
 
Concerning the previous results, further tests were done comparing 2D and 
3D cultures regarding this time the effect of combined therapies. The results are 
preliminary and further tests are needed with the drugs alone to confirm the 
results and have higher statistical significance.  
In overall, no additional effect can be observed with the combination of 
mTOR inhibitors with CDK inhibitors and no differences exist between both 
culturing methods (Table 7).  
Assays blocking effects of KRAS mutant constitutive pathway activation 
with PI3K and MEK inhibitors have already proven to bring more sensitiveness 
to 2D cultures for LKR and MetA lines. Combination of both inhibitors brought 
down the viability of LKR spheres to the same level as in 2D cultures (Figure 
35), which possibly indicates a better outcome for cells cultured in 3D when 
therapies are combined, bringing promising perspectives to in vivo assays 
(Table 7). 
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Figure 35. Dose effect of combined MEK and PI3K inhibitors on 2D and 3D viability upon 
72h treatment. A bigger impact is noticed on LKR 3D cultures when MEK and PI3K inhibitors 
are combined, compared with the single treatment shown in Figure 31. 
 
Table 7. Therapy combinations. The percentage of the end point viability reached by cells is 
represented upon increasing dose treatments. Comparisons can be made looking at the drugs 
effect alone. MEK and PI3K inhibition had higher effectiveness when combined for LKR in 3D. 
 
End point viability %  MetA LKR D 
Name Description 2D 3D 2D 3D 2D 3D 
PD0332991 dihydrochloride (µM)  42 31 31 48 76 48 
PD0332991 dihydrochloride (µM) + AZD8055 (nM) CDK + mTOR inhibitors 25 36 49 33 42 64 
GDC941 (nM)  16 16 5 38 30 27 
Trametinib (nM)  23 17 10 46 20 9 
Trametinib (nM) + GDC941 (nM) MEK + PI3K inhibitors 12 9 10 9 18 8 
 
KRAS mutants are very sensitive to the proteasome inhibitor Bortezomib 
both in 2D and 3D. In this sense, the Bortezomib IC20 dose was combined with 
IKK-β and MEK inhibitors. A big viability decrease was mainly observed for 
LKR 3D cultures, but 2D is still more sensitive (Figure 36, Table 8).  
 
 
 
 
 
 
 
 
 
 
Figure 36. Dose effect of Trametinib combined with the corresponding IC20 dose for 
Bortezomib on 2D and 3D viability upon 72h treatment. A bigger impact is noticed on 3D 
cultures when MEK and proteasome inhibitors are combined.  
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Table 8. IC50 for therapy combinations. Drugs effect when alone or combined. A significant 
decrease on LKR 3D cultures happens when Bortezomib IC20 dose is added to Trametinib. 
 
 
 
 
 
 
Results are still preliminary, therefore conclusions about the synergistic 
effect of combined therapies will require further analysis.  
 
3.7- MEK inhibition resistance 
 
Attempts from other lab members to generate Trametinib resistant cell lines 
have been made. We tried to generate resistant cells using the 3D cultures and 
then compare the sensitivity in 2D and 3D. For this purpose, 10 day treatment 
of 3D cultures with Trametinib and reseeding on 2D and 3D cultures again, 
generated cultures less sensitive to Trametinib. However, 2D and 3D cultures 
were equally affected (Figure 37, Table 9). 
 
 
 
 
 
 
 
 
 
Figure 37. Dose effect of Trametinib on 2D and 3D Trametinib resistant cells upon 72h 
treatment. For both cell lines and both culture methods long periods of Trametinib exposure 
induces cells resistance turning them less sensitive to the MEK inhibitor.  
 MetA LKR D 
Name 2D 3D 2D 3D 2D 3D 
BMS-345541 (µM) 0.6 1.1 1.6 2.3 1.2 1.4 
Trametinib (nM) 0.5 0.6 0.3 43 1 0.4 
Bortezomib (nM) 0.1 0.1 0.1 0.2 0.2 0.3 
BMS-345541 (µM) + Bortezomib (nM) 0.1 0.1 0.2 0.5 0.2 0.5 
Trametinib + Bortezomib (nM) 0.1 0.2 0.1 0.4 0.1 0.2 
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Table 9. IC50 for 2D and 3D Trametinib resistant cells. IC50 increases after long periods with 
Trametinib treatment. NA means that cells did not reach IC50.  
 
 
 
 
 
 Most likely longer treatment periods will be necessary to result in a more 
resistant model.  
 It was previously shown that tumor spheroids are excellent models to 
study antitumor drug resistance [60]. It would then be interesting to explore 
whether cell organization in 3D has any influence in the acquisition of 
resistance upon certain treatments.  
 
3.8- KRAS knockdown spheres 
 
 Our final objective was to use small interfering RNA (siRNA) to 
manipulate gene expression and generate, in spheres, a stable knockdown 
selective for oncogenic KRAS. Cells are generally dependent on KRAS mutant 
and its knockdown is known to influence cell viability. A stable model would 
work as a control in future drug assays to interpret how susceptible WT KRAS 
cells are towards the same tested treatments [51]. 
 As described in detail in material and methods, three different 
approaches were used to knockdown oncogenic KRAS in 3D cultures. 
DharmaFECT transfection reagents were used in already established spheres 
with 48h and in cells right before seeding spheres. Both methods had no impact 
on cell growth after 3 days, indicating a deficient transfection despite the use of 
high siRNA concentrations (Figure 38). In the first case transfection might have 
been blocked to penetrate the spheres due to the dense matrigel composition, 
whereas in the second trial transfection appeared to be toxic and did not allow 
spheres to form.  
 The same situation was observed with the Oligofectamine transfection 
reagent which was used to transfect 2D cells before its transfer into 3D cultures 
(Figure 38). The positive cell survival in both Scramble control and siRNA 
 LKR D 
Name 2D 3D 2D 3D 
Trametinib (nM) 0.3 43 1 0.4 
Trametinib Resistant 2.5 NA 3.5 1.4 
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KRAS pool shows that, possibly, mainly non-transfected cells were used to 
form spheres. Lysates from this technique were collected and await for qPCR 
analysis in order to confirm the efficient transfection. 
 
 
 
 
 
 
 
 
Figure 38. Viability of spheres after different transfection methods. The constant 
luminescence signal between the controls Risc-Free and Scramble and the siRNA KRAS pool 
samples shows the deficient transfection. 
 
siRNA transfection in spheres has shown to be more challenging than 
expected, and further efforts are required to achieve a successful knockdown. 
Exploring the use of a KRAS inducible system would therefore overcome 
transfection issues and it is surely not discarded from future directions. 
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Chapter 4 
 
 
Concluding Remarks 
 
3D culture systems are well known for their ability to better mimic in vivo 
conditions. They are able to recreate features of the tumor biology, better 
predicting therapeutic outcomes. However, the use of this kind of platform for 
NSCLC cells driven by the mutant KRAS, has not been much explored to the 
date.   
Here we show that KRAS mutant cells from a mouse model are able to 
grow and survive particularly better in matrix embedded systems. Matrigel 
2.5% (v/v) confers the appropriate conditions to culture these cells and is 
simultaneously suitable for large-scale high throughput screenings, as was also 
shown by a preliminary screen. CellTiter-Glo assay also showed to be an 
accurate and sensitive method to monitor cell viability. Its lysing properties are 
indicated to penetrate the spheres. 
Morphologically, spheroids have a very smooth out-layer and tend to 
form adhesion complexes between cells. Cell cross communication with factors 
or stimulus may then occur at a higher level in 3D cultures. TEM images 
showed particular differentiation features in the D cell line. It is a very well 
organized structure that forms defined acini and is positive for E-cadherin. 
Evaluation of the pathway activation showed a persistent increase in the 
activity of p-ERK on 3D cultures for all of the tested cell lines. However, the 
culture system does not seem to have an influence on the activity of other 
proteins such as p-AKT and p-MLC, which showed no apparent variation.    
Differences on KRAS dependencies between 2D and 3D cultures were also 
subject of study. We targeted KRAS downstream effectors or other pathways 
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that have been shown to play a role on the survival of cells harboring KRAS 
mutations. Results showed that there are some differences in drug sensitivity 
between both 2D and 3D settings, but that they are usually cell line dependent.  
Differences are especially evident for the D line. This cell is apparently 
more sensitive to inhibitors like CDK, MEK and PI3K when cultured in 3D, 
whereas the opposite happens for the MetA and LKR lines, which are more 
responsive in 2D for the same targets of the KRAS pathway. 
On the other hand, MetA and LKR spheroids showed a good response 
towards structural stability inhibitors like Paclitaxel and Latrunculin, while it 
was ineffective for 2D cultures and the D line both in 2D and 3D settings. 
The results obtained also suggest that it may be an important link between 
spheroid structural organization and its responsiveness and that this link is 
worth to be explored further. Interestingly, the D line, which displayed the 
most well organized 3D structure, is the only one that is more vulnerable to 
KRAS pathway targets in a 3D setting.  On the other side, MetA and LKR lines, 
which showed to be 3D randomly organized, are the most sensitive to 
structural stability inhibitors. 
In summary, we have developed a method to grow NSCLC cell lines in 3D 
and quantify cell viability after drug treatment. Results demonstrate that 2D 
and 3D cultures show different sensitivity to certain inhibitors. Therefore, 
testing automatically large sets of drugs may eventually highlight new 
exclusive 3D targets that will reflect better the drug response in an in vivo 
setting. 3D cultures are then promising tools with potential to contribute for the 
development of new anti-cancer agents in the future. 
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Supplementary Information 
 
Supplementary Information 1. D line does not show villi in 2D cultures. Contrarily to 3D 
cultures, TEM images show the absence of microvilli in the D cell line.  
 
 
 
 
 
 
 
 
 
 
Supplementary Information 2. Drug dose assays. Differences can be observed between 2D and 
3D for some inhibitors. However the differences are cell line dependent.  
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